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Abstract

Background: Muscle mass has been found to be highly correlated with patient outcomes.
Techniques to identify patients with low muscularity include computed tomography (CT) and
bioelectrical impendence analysis (BIA) however disadvantages of cost, exposure to radiation
and limited access make these measurements unavailable to the average dietitian. Urinary
creatinine excretion (UCE) and the subsequent estimation of creatinine height index (CHI) have
been strongly associated with muscularity and outcomes, however, these require a 24-hour urine
collection. The postulation that UCE may be predicted from patient variables, through
mathematical modeling, would avoid the need for a 24-hour urine collection and may be
clinically useful.
Methods: Input variables of age, height, weight, gender, plasma creatinine, urea nitrogen,
glucose, sodium, potassium, chloride, carbon dioxide, and magnesium, from a deidentified data
set of 967 patients who had UCE measured in the previous 5 years, were used to develop models
to predict UCE. The model identified with the best predictive ability was validated using fourfold cross validation and using a separate data set not used to construct the model. Model
predicted UCE and CHI were compared to measures of muscularity. The model was then
retrospectively applied to a convenience sample of 120 critically ill veterans to examine degree
of low muscle mass observed in the cohort and if UCE and CHI were associated with outcomes
in hospitalized veterans.
Results: A model to estimate UCE was identified utilizing the input variables of plasma
creatinine, plasma BUN, age and weight which was found to be highly correlated, moderately
predictive of UCE and statistically significant. Model predicted UCE was found to be highly
correlated with accepted measures of muscularity. Applying the model to a cohort of subjects
identified that 44.2% of the subjects had CHI levels ≤ 60% and were considered to have severe
sarcopenia. Subjects with model estimated CHI ≤ 60% were found to have significantly lower
body weight, BMI, plasma creatinine, albumin and prealbumin levels. Subjects with CHI ≤ 60%
were found to be 8.0 times more likely to be diagnosed with malnutrition and 2.6 times more
likely to be readmitted in 6 months. Subjects with low CHI trended towards longer hospital and
ICU LOS, however it did not meet statistical significance. The NUTRIC score was found to have
no relationship with the presence of malnutrition.
Conclusion: The development of a model which predicts UCE and correlates with muscle mass
offers a novel method for the RDN to readily identify patients with sarcopenia on hospital
admission. This method could allow the RDN to quickly screen new admissions for potential
sarcopenia without the use of CT or DEXA scans and without the inconvenience of a 24-hour
urine collection by using readily available patient variables
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Introduction
Consensus guidelines from the Society of Critical Care Medicine (SCCM) and the
American Society of Parenteral and Enteral Nutrition (ASPEN) have recommended that
measurement of actual energy expenditure, through the use of indirect calorimetry, be used to
determine energy requirements.1 Actual measurement allows for individualized and targeted
energy goals for the patient.1 Similarly, The European Society for Parenteral and Enteral
Nutrition (ESPEN) recommends that energy intake be determined using indirect calorimetry if
the patient is mechanically ventilated or, if calorimetry is not available, to use oxygen
consumption, VO2, from a pulmonary arterial catheter or carbon dioxide output, VCO2, derived
from a ventilator, to determine needs.2
In contrast, for protein intake, the SCCM/ASPEN guidelines acknowledge that although
protein needs in the critically ill appear to be higher than previously thought, determining
individual requirements is difficult. As a result, the current recommendations are to provide
between 1.2 to 2.0 g protein/kg actual body weight per day.1 The protein recommendation from
ESPEN is that 1.3g protein/kg per day can be delivered progressively.2 These stark differences
between energy and protein recommendations underscore the dilemma facing the practicing
clinician. Calorie recommendations are based off of actual measurement of patient specific
parameters whereas protein recommendations are based off of weight without any compensation
for metabolic state, severity of illness or underlying muscularity. The range of protein intake, as
recommended in the SCCM/ASPEN guidelines, when calculated for an individual patient are so
wide and non-specific that they are not clinically useful.
Previous studies attempted to identify protein requirements in the critically ill. Although
protein intake, when provided above maintenance amounts, has been found to be beneficial,
2

studies have failed to consistently identify the protein intake most associated with improved
outcomes.3–8 Although positive retrospective or observational studies have identified associations
between higher protein intake and improved outcomes, these findings have been unable to be
confirmed in randomized control trials (RCT).9–11 It has been suggested that lack of positive
findings and failure to show effectiveness of nutrition therapy in these studies may be due to
their failure to control for patient population type, the suitability of included patient types or
metabolic state.12,13 Several studies have observed that targeted nutrition therapy appears to be
the most beneficial in only patient specific groups such as those at high nutritional risk, with
malnutrition or with low muscularity.14–18

Chapter 1: Significance/Literature Review

Importance of skeletal muscle
It is well recognized that skeletal muscle has significant purpose beyond that of its
structural functions. Skeletal muscle is an important metabolically active and homeostatic organ,
accounts for approximately 50% of all body protein and plays key roles in immune function,
glucose metabolism and protein synthesis.19,20 Oft forgotten, muscle plays a pivotal role in
whole-body protein metabolism, which is of particular importance during acute stress or
illness.21 All organs and tissues undergo protein turnover in which the rate of protein breakdown
is balanced with the synthesis of new proteins. In the fed state, amino acids from food stuffs
supply the needed precursors for new protein synthesis. Under normal conditions, ingested
amino acids are incorporated into muscle to replace the amino acids which were lost during
fasting, with the overall result being that the gains achieved are balanced with the losses. When
nutrient intake is insufficient, muscle protein becomes the principal reservoir of needed amino
3

acids for all other organs and tissues.21 Normal protein turnover and maintenance of other
essential organs and tissues can continue provided adequate muscle mass is available for
cannibalism.21
In the setting of acute illness, requirements for amino acids, intermediate metabolites and
minerals from skeletal muscle increases due to increased synthesis of acute phase proteins,
synthesis of protein components of the immune system and synthesis of proteins necessary for
wound healing.12,20–22 Conversely, the anabolic response to feeding is impaired and loss of lean
body mass may not be reversible by nutrition support.23,24 Mediators of this process are not
entirely clear, however the counter-regulatory hormones, glucagon, catecholamines and
glucocorticoids are generally elevated in the critically ill and stimulate amino acid catabolism.23
In critically ill patients, directly correlated with the severity of the injury, increases in
proinflammatory cytokines, glucocorticoids and oxidative stress reinforce the effect of catabolic
hormones and contribute to muscle wasting.24 Critical illness thus initiates a cascade of events
that lead to accelerated protein degradation, decreased rate of synthesis of selected proteins and
increased catabolism and nitrogen loss.23
The overall consequence of this rapid body protein remodeling is metabolic imbalance in
which “net muscle protein loss greatly exceeds the gain of protein elsewhere and whole-body
nitrogen balance becomes strongly negative”.22 Additionally, in the acute care setting, when the
calorie provision is insufficient, amino acids from skeletal muscle are broken down to provide
the body with energy by way of gluconeogenesis.19
Thus, acute illness results in a large protein loss from the body over a short period of
hospitalization. Studies have further shown that this is largely muscle mass and clinically
significant losses have been quantified.13,25 Furthermore, immobility associated with
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hospitalization causes atrophy of skeletal muscle and additionally contributes to protein loss.23
These net losses ultimately impair the immune response and may increase morbidity and
mortality of the patient.23 It has been suggested that poor outcomes may occur when the
increased amino acid uptake, to respond to the injury, is limited by both the lack of adequate
exogenous protein provision and inadequate underlying muscle mass available to release amino
acids.22 Experts have proposed that providing sufficient exogenous amino acids could improve
outcomes by “increasing central protein synthesis, optimizing the inflammatory response,
mitigating the loss of muscle protein, and mitigating muscle atrophy”.22
As studies have observed that targeted protein intake appears to be the most beneficial in
only patient specific groups such as those at high nutritional risk, with malnutrition or with low
muscularity, it appears that nutrition risk is related to outcomes in the acutely ill.14–18 These
findings, coupled with the recognition of the large protein losses and protein redistribution that
occurs in acute illness, suggest that for personalized nutrition therapy to be beneficial, the patient
with low muscularity or with malnutrition needs to be identified.13,15,16,26 The aims of nutritional
therapy in the critically or acutely ill patient are thus to blunt the loss of lean body mass (LBM)
or restore body protein mass and to provide adequate protein and energy.4,24
As low muscle mass has been found to be predictive of outcomes, it may also be an
important determinant of protein requirements.27 Measurement and assessment of LBM may thus
provide important insights into patient’s protein needs as those who have low muscularity will
have less to cannibalize and will require greater exogenous provision.28 Monitoring muscle mass
may additionally provide a method to evaluate the effect and timing of the prescribed nutrition
interventions. Unfortunately, practitioners generally rely on readily available measures, such as
weight or body mass index (BMI), which do not relate to underlying muscularity, and may
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ultimately prevent the clinician from directing interventions towards preserving or restoring
muscle mass.29
Widely used nutrition screening criteria and earlier diagnostic criteria for malnutrition
have not included evaluation of muscle within their definition and instead focus on BMI and
weight loss.30 This results in failure to identify low muscle mass and leads to emphasis on energy
provision and weight maintenance rather than protein intake and targeting muscle.19 In contrast,
both the AND/ASPEN and GLIM malnutrition criteria include identification of reduced muscle
as a key diagnostic criteria.31,32
Recent recommendations have been made in an attempt to shift the focus of nutrition into
managing and reducing the loss of muscle mass to improve patient clinical outcomes.19 These
recommendations propose that muscle mass should be at the core of nutrition management
strategies. Patients should be screened for low muscle mass, and tools and techniques should be
used to directly assess muscle mass within the nutritional assessment. Another key
recommendation is that nutrition intervention should be optimized to focus on muscle rather than
weight. To achieve these goals, the authors suggest that a change in focus and practice is
required in how nutrition clinicians screen, assess and treat patients.19

Studies which have examined the relationship between muscularity and outcomes
Low muscle mass, as measured by a variety of methods, has been found to be associated
with adverse outcomes in the critically ill and other hospitalized inpatient populations, Table 1.
Studies have observed significant relationships between low muscle mass, or loss of muscle mass
and in-hospital mortality, 30-day, 60-day, or 6-month mortality, higher disease severity scores,
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hospital length of stay (LOS), pneumonia, respiratory failure, need for re-intubation and organ
failure.17,25,28,33–42
A recent retrospective study of 279 intensive care unit (ICU) patients who had computed
tomography (CT) scans was conducted to examine if low muscle mass, as determined from CT
scans, was associated with outcomes.36 They observed that 68% of the population was
sarcopenic and that low muscle mass was significantly associated with older age, p < .001, more
comorbidities, p = .009, and longer hospital LOS, p = .043. Importantly, on logistic regression,
30-day mortality was found to be strongly associated with low muscle area (OR 0.98, p = .004).
Loosen et al37 conducted an exploratory observational study of 155 patients admitted to
the medical ICU who had CT scans on admission. They calculated skeletal muscle area to
identify sarcopenia and mean skeletal muscle attenuation (MMA) to determine muscular fat
deposition, myosteatosis, and then explored if these parameters were related to outcomes. They
identified no differences in short term outcome, of ICU survival, between those with or without
sarcopenia or between those with or without myosteatosis. However, they did observe significant
differences in 6-month and 1-year survival. Patients with low skeletal muscle or high amounts of
fatty infiltration of muscle were more likely to have died at 6-months or 1-year time points.
Binary logistic regression analysis revealed both low muscle mass (OR, 0.979, p = .025) and
fatty infiltration (OR, 0.964, p = .014) as prognostic of 6-month mortality.
Jaitovitch et al38 conducted a prospective, observational study of 423 subjects who had
been admitted to the medical ICU and who had a CT scan within the first 24-hours of admission.
They sought to determine if muscle mass and fat mass, as identified on CT scan, were associated
with survival and disability at hospital discharge. Disability was defined as discharged to a
facility or home with assistance compared to discharged home without assistance. They observed
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that larger muscle mass was significantly associated with decreased odds of mortality at 6months (OR 0.96 per cm2 increase in mass, CI 0.94-0.97, p < .001) and with decreased odds of
disability (OR 0.98 per cm2 increase in mass, CI 0.96-0.99, p = .012). There was no statistically
significant association between fat mass and survival, or disability observed. Larger muscle area
was the only clinical parameter that remained significantly associated with survival after
multivariable adjustments.
Looijard et al17 conducted a retrospective database study of adult patients admitted to a
mixed medical surgical ICU who were on ventilators and receiving enteral tube feedings. They
examined data from 739 patients who had CT scans shorty after admission which they used to
identify low muscle mass. Patients were divided into 3 groups: normal skeletal muscle area
(SMA), low SMA and combined low SMA with low skeletal muscle density (SMD) based on CT
scans. Patients were additionally stratified based on whether they received <1.2 or >1.2g
protein/kg/day. The researchers sought to examine whether muscle mass and quantity of protein
intake is associated with outcomes of 60-day and 6-month mortality. They observed a high
prevalence of both low SMA and low SMD, 445 (60%) were found with low SMA, of those 200
(45% of the low SMA group) were found to have low SMA and low SMD. Patients with low
SMA were older, p < .001, lower weight, p < .001, and had higher APACHE II scores, p < .001
than those with normal SMA. Low SMA group and Low SMA and SMD groups had higher 60day and 6-month mortality, all p < .001, compared to normal SMA. In the combined low SMA
and Low SMD group, 60-day and 6-month mortality were significantly lower in those that
received protein intake >1.2g/kg/day, p < .001. The authors concluded that optimal nutrition
strategies may differ between patients with certain sub-groups benefitting while others do not.
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Their study suggests that patients with low SMA and low SMD may benefit from early higher
protein intake.
Imamura et al39 retrospectively examined a group of adults who underwent emergency
surgery for colonic perforations who had CT scans the day of surgery. They further stratified
patients by age into <75 years or ≥75 years old. They examined if there was a correlation
between psoas muscle mass and LOS. A total of 46 subjects met criteria. The older group had
significantly lower psoas muscle area, 961mm2 vs 1622mm2, p < .001, compared to the younger
group. A significant negative correlation, r = .23, p = .02, was observed between LOS and psoas
area in the younger group but not in the older group. They suggest that the older group may have
generalized sarcopenia however many elderly transferred to other facilities for post-op care thus
true LOS may be underestimated.
Fuchs et al40 conducted a prospective observational study of 231 patients in medical and
surgical ICUs who were recently extubated. They examined the effect of low skeletal muscle as
determined from the skeletal muscle index, SMI, measured from CT scans on outcomes at 30
days after extubation. They observed that patients with low SMI had significantly greater rates of
pneumonia, p < .001, 30-day mortality, p = .004, reintubation within 72 hours, p < .02, and
respiratory failure within 30-days of extubation, p < .02 when compared to those with normal
SMI. Low skeletal muscle was found to be a strong predictor of pneumonia, OR 0.96, p < .002,
and 30-day mortality, OR 0.94, p < .03.
Abramowitz et al41 conducted a retrospective data base analysis of NHANES data of
11,687 adult subjects who had dual energy x-ray absorptiometry (DEXA) scan results. They
included subjects with BMIs between 18.5 and 40. They sought to determine if there was a
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Table 1. Studies Examining Relationship of Muscle Mass on Outcomes
Study
Joyce
2020

Subject
Type and
Number
Mixed med
surg ICU;
279 subjects

Design

Observation or
Intervention and Duration

Retrospective
chart review

Identified low muscle mass
based on CT scans.
Examined whether low
muscle mass was associated
with outcomes.

Results

Loosen
2020

Medical
ICU; 155
subjects

Exploratory
observational
study

Examined CT scans on ICU
admission and calculated
skeletal muscle area to
determine sarcopenia and
mean skeletal muscle
attenuation (MMA) to
determine muscular fat
deposition. Explored if these
parameters were related to
outcomes.

189/279 (68%) were identified as being
sarcopenic. Those with sarcopenia were
significantly older, p<0.001, had more
comorbidities, p<0.009, and hospital LOS,
p<0.04. Using logistic regression, 30-day
mortality was associated with low muscle area
(OR 0.98, p = 0.004).
No differences in ICU survival between those
with or without sarcopenia or between those with
or without myosteatosis. Observed patients with
low skeletal muscle or high amounts of fatty
infiltration of muscle were more likely to have
died at 6-months or 1-year time points. Binary
logistic regression analysis revealed both low
muscle mass (OR, 0.979, p=0.025) and fatty
infiltration (OR, 0.0.964, p=0.014) as prognostic
of 6-month mortality.

Jaitovich
2020

Medical
ICU; 423
patients

Prospective
observational
study

Looijard
2020

Mixed medsurg ICU;
on
ventilators;
739 subjects

Retrospective
Database search

Evaluated CT scans obtained
within the first 24-hours of
ICU admission. Determined
if muscle mass, fat mass and
bone density, as identified on
CT scan, were associated
with survival and disability at
hospital discharge
Patients were divided into 3
groups: normal skeletal
muscle area (SMA), low
SMA and combine low SMA
with low skeletal muscle
density (SMD) based on CT
scans. Patients were stratified
based on whether they

Larger muscle mass was significantly associated
with decreased odds of mortality at 6-months
(OR 0.96 per cm2 increase in mass, CI 0.94-0.97,
p< 0.001) and with decreased odds of disability
(OR 0.98 per cm2 increase in mass, CI 0.96-0.99,
p=0.012). There was no statistically significant
association between fat mass and survival, or
disability observed.
445 (60%) were found with low SMA, of those
200 (45% of the low SMA group) were found to
have low SMA and low SMD. Patients with low
SMA were older, p<.001, lower weight, p<.001,
and had higher APACHE II scores, p<.001 than
those with normal SMA. Low SMA group and
Low SMA and SMD groups had higher 60-day
and 6-month mortality, all p<.001, compared to
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Notes
Baseline sarcopenia was
highly prevalent.

Muscle area was the only
clinical parameter that
remained significantly
associated with survival
after multivariable
adjustments.

Unclear role of muscle
quality versus muscle
quantity. They may play
equally important roles.

Lower muscle mass was
associated with worse
outcomes. Higher protein
intake was associated
with lower mortality in
those with low muscle
mass but not those with
normal muscle mass.

received <1.2 or >1.2g
protein/kg/day. Examined
whether muscle mass and
quantity of protein intake is
associated with mortality.

normal SMA. In the combined low SMA and
Low SMD group, 60-day and 6-month mortality
were significantly lower in those that received
protein intake >1.2g/kg/day, p<.001.

Imamura
2019

Adults who
underwent
emergency
surgery for
perforated
colons; 46
subjects

Retrospective
chart review

Patients had CT scans on day
of emergency surgery;
stratified patients by age <75
years or >/=75 years old.
Examined if there was a
correlation between psoas
muscle mass and mortality.

46 subjects met criteria. The older group had
significantly lower psoas muscle area, p<.0001.
A significant negative correlation, r=0.23, p=.02,
was observed between LOS and psoas area in the
younger group but not in the older group.

Fuchs
2018

Adults;
mixed medsurg ICU;
recently
extubated;
231 subjects

Prospective
observational

Examined the effect of
skeletal muscle
measurements from CT scans
on outcomes at 30 days after
extubation

Pts with low skeletal muscle index had
significantly greater rates of pneumonia, p<.0001,
30-day mortality, p<.004, reintubation within 72
hours, p<.02, and respiratory failure within 30days of extubation, p<.02. Low skeletal muscle
was a predictor of pneumonia, OR 0.96, p<.002,
and 30-day mortality, OR 0.94, p<.03.

Abramowitz
2018

Adults with
BMIs
between
18.4 and 40;
11,687
subjects

Retrospective
data analysis

Examined data from
NHANES to determine if
there was a relationship
between low muscle mass, as
measured by DEXA, and risk
of death. Muscle mass was
estimated from the
appendicular skeletal muscle
mass index.

Shibahashi
2017

Adults with
sepsis
admitted to
the ICU, 150
subjects

Retrospective

Lean skeletal muscle mass
was estimated from the crosssectional area of the psoas
and paraspinal muscles at L3
vertebrae. Patients were
stratified to survived and

14% of all subject were found to have low muscle
mass. Low muscle mass was not limited to those
with low percent total body fat (%TBF). During
their time frame of interest, 1,819 subjects died.
When separated by muscle mass status, within
each BMI category the hazard ratio for death was
higher for subjects with low muscle mass,
p<.001. When examining subjects with preserved
muscle mass alone, there was a significantly
increased risk of death among those who were
obese compared with overweight, HR 1.23, 95%
CI 1.04-1.47.
Patients which survived had significantly larger
muscle mass than those who did not, 43.3 cm 2 vs
36.8 cm2, p<.001. Skeletal muscle area was found
to be an independent predictor of in-hospital
mortality, OR 0.94, 95% CI 0.90-0.97, p <.001.
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Longer LOS associated
with low muscle mass
only in younger age
group. Many elderly
transferred to other
facility for post-op care
thus true LOS may be
underestimated.
Skeletal muscle is a
strong predictor of
outcomes

Skeletal muscle mass is a
significant mediator and
modifier of the
relationship of BMI and
mortality.

Low skeletal muscle mass
is associated with higher
in-hospital mortality

deceased and into 60-80
years and >80 years of age.

When age groups were examined, skeletal muscle
area remained significant regardless of age.

Thibault
2016

Adults
admitted to
mixed Medsurg ICU,
931 subjects

Multi-site
Prospective
observational

Obtained BIA measurements
on day 1 of ICU admission to
estimated fat-free mass.
Examined if there was a
relationship between BIA
measurements and 28-day
mortality and disease severity

BIA measures of fat-free mass were significantly
lower in non-survivors than survivors, 4.10 vs
4.59, p<.00. Disease severity scores were also
significantly worse in those patients with lower
fat-free mass, 21.8 vs 17.7, p<.001. Variables
significantly associated with 28-day mortality
were admitting BIA measurement of fat-free
mass, APACHE II score, surgical diagnosis and
increasing age. BMI was not found to be a
significant variable.

Future studies should be
designed to assess
whether nutrition
interventions could
change outcomes

Weijs
2014

Adults
admitted to
mixed MedSurg ICU,
who had a
CT scan
within the
first 4 days,
240 subjects
Adult
trauma
patients with
CT scans on
admission,
148 subjects

Retrospective
chart review

Examined the relationship
between muscle mass, as
determined from CT scans,
and BMI on hospital
mortality

Low muscle mass was found in 63% of all
subjects. Patients with low muscle area had
higher hospital mortality, 38.2% vs 12.5%,
p<.001. Regression analysis demonstrated that
muscle area, sex and APACHE II score where
independent predictors of mortality while BMI
and diagnosis were not.

Low skeletal muscle mass
is an independent
predictor of mortality in
ventilated patients. BMI
appeared to have no
impact on mortality.

Retrospective
chart review

CT scans were used to
identify both skeletal muscle
and adipose tissue crosssectional areas. They sought
to determine if low
muscularity or low adiposity
adversely affected outcomes.

Based on BMI alone, 57% were overweight or
obese and 7% were underweight. Based on CT
scan measurements, 71% of all subjects were
sarcopenic. Significantly more patients with
sarcopenia died compared to those not
sarcopenic, 32% vs 14%, p=.018. After
controlling for age, sex and injury severity, low
muscle index but not BMI or low albumin, was
associated with hospital mortality, OR =0.93,
95% CI 0.87-0.99, p =.025. Sarcopenic patients
had significantly lower ventilator-free, p = .004,
and ICU-free days, p=.004. No differences were
noted in visceral adipose tissue mass between
sarcopenic and non-sarcopenic patients. Adipose

BMI poorly identifies low
muscle mass and that low
muscularity has
significant implications
on outcomes.

Moisey
2013
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tissue was not associated with mortality,
ventilator-free or ICU-free days.

Puthucheary
2013

Gruther
2008

Adults,
mixed medsurg ICU, on
vents longer
than 48
hours and
ICU stays
longer than
7 days; 63
subjects
Adults,
mixed medsurg ICU;
125 subjects

Prospective
observational
study

Performed serial ultrasound
measurements of rectus
femoris and muscle biopsies
on ICU days 1,3,7 and 10.
Muscle protein synthesis,
breakdown and balance was
determined by leucine
incorporation using leucine
infusions on days 1 and 7

Muscle cross-sectional area decreased from
baseline by 17.7%, p <.001, by ICU day 10 and
the ratio of protein to DNA by 29.5%, p <.001.
Leg protein breakdown was elevated compared to
synthesis, p =.05, resulting in a net catabolic
balance. Increasing organ failure score was
correlated with change in muscle cross sectional
area, r = 0.23, p < .001.

Skeletal muscle wasting
occurred early and rapidly
in critically ill patients
and appeared to be due to
both decreased synthesis
and increased muscle
breakdown.

Prospective
observational
study

Conducted ultrasound
measurements of the rectus
femoris and vastus
intermedius muscles and
estimated muscle layer
thickness. Interested in
identifying muscle wasting in
ICU patients and whether
there was a relationship
between muscle and length of
stay (LOS).

Observed a significant negative correlation
between admission muscle layer thickness and
LOS, p = .005

Muscle wasting was best
described by using a
logarithmic function

ICU = intensive care unit; Med = medical; Surg = surgical; LOS = length of stay; CT = computed tomography; BMI = body mass
index
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relationship between low muscle mass, as measured by DEXA, and risk of death at a mean time
point of 9 years. Muscle mass was estimated from the appendicular skeletal muscle mass index.
They observed that 14.1% of all subjects had low muscle mass and that low muscle mass was not
limited to those with low percent total body fat (%TBF). During their time frame of interest,
1,819 subjects died. When separated by muscle mass status, within each BMI category the
hazard ration for death was higher for subjects with low muscle mass, p < .001. When examining
subjects with preserved muscle mass alone, there was a significantly increased risk of death
among those who were obese compared with overweight, HR 1.23, 95% CI 1.04-1.47. Skeletal
muscle mass was observed to be a significant mediator and modifier of the relationship of BMI
and mortality and that muscle mass altered the relationship of BMI with %TBF.
Shibahashi et al42 conducted a retrospective study of 150 adults > 60 years of age who
were admitted to the ICU with sepsis and had a CT scan performed the day of ICU admission.
They were interested if whether decreased skeletal muscle mass is associated with mortality.
Lean skeletal muscle mass was estimated from the cross-sectional area of the psoas and
paraspinal muscles at L3 vertebrae. Patients were stratified into survived and deceased groups
and into 60-80 years and >80 years of age groups for analysis. Patients which survived had
significantly larger muscle mass than those who did not, 43.3 cm2 vs 36.8 cm2, p < .001. Skeletal
muscle area was found to be an independent predictor of in-hospital mortality, OR 0.94, 95% CI
0.90-0.97, p < .001. When age groups were examined, skeletal muscle area remained significant
regardless of age. The authors propose that identifying patients with low muscularity may allow
for earlier intervention.
Thibault et al33 conducted a large multi-site prospective observational study of
931patients admitted to mixed medical surgical ICUs who underwent BIA measurements to

14

assess fat-free mass on day of ICU admission. They were interested in examining if there was a
relationship between BIA measurements and 28-day mortality and disease severity, APACHE II
score. BIA measures of fat-free mass were significantly lower in non-survivors than survivors,
4.10 vs 4.59, p < .001. Disease severity scores were also significantly worse in those patients
with lower fat-free mass, 21.8 vs 17.7, p < .001. Variables significantly associated with 28-day
mortality were admitting BIA measurement of fat-free mass, APACHE II score, surgical
diagnosis and increasing age. BMI was not found to be a significant variable. They concluded
that fat-free mass measured on ICU admission by BIA is associated with 28-day mortality.
Weijs et al28 conducted a retrospective chart review of 249 patients who were admitted to
a mixed medical-surgical ICU, were on ventilators and who had a CT scan within the first 4
days. They were interested if there was a relationship between muscle mass, as determined by
the CT scan, BMI and outcomes. They observed that 63% of all patients had low muscle mass.
Patients with low muscle area had higher hospital mortality, 38.2% vs 12.5%, p < .001.
Regression analysis demonstrated that muscle area, sex and APACHE II score where
independent predictors of mortality while BMI and diagnosis were not. When muscle area was
examined as a continuous variable and not as a sex related cut-off category, sex disappeared as
an independent predictor of mortality.
Moisey et al34 conducted a retrospective study of 148 adult patients admitted to their
trauma unit who had a CT scan on day on admission. CT scans were used to identify both
skeletal muscle and adipose tissue cross-sectional areas. They sought to determine if low
muscularity or low adiposity adversely affected outcomes. On the basis of BMI alone, 57% were
overweight or obese and 7% were underweight. In stark contrast, based on CT scan
measurements, 71% of all subjects were sarcopenic. Significantly more patients with sarcopenia
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died compared to those not sarcopenic, 32% vs 14%, p = .018. After controlling for age, sex and
injury severity, low muscle index but not BMI or low albumin, was associated with hospital
mortality, OR =0.93, 95% CI 0.87-0.99, p = .025. Sarcopenic patients had significantly lower
ventilator-free, p = .004, and ICU-free days, p = .004. No differences were noted in visceral
adipose tissue mass between sarcopenic and non-sarcopenic patients. Adipose tissue was not
associated with mortality, ventilator-free or ICU-free days. The authors conclude that BMI
poorly identifies low muscle mass and that low muscularity has significant implications on
outcomes.
Puthucheary et al25 conducted a prospective observational study on 63 subjects admitted
to a mixed medical-surgical ICU who were anticipated to be on a ventilator longer than 48 hours
and require ICU stays of greater than 7 days. They were interested in characterizing the time
course and pathophysiology of muscle loss in the critically ill. They performed serial ultrasound
measurements of rectus femoris and muscle biopsies on ICU days 1,3,7 and 10. Additionally,
muscle protein synthesis, breakdown and balance was determined by leucine incorporation using
leucine infusions on days 1 and 7. They observed that muscle cross-sectional are decreased from
baseline by 17.7%, p < .001, by ICU day 10 and the ratio of protein to DNA by 29.5%, p < .001.
Leg protein breakdown was elevated compared to synthesis, p = .05, resulting in a net catabolic
balance. Increasing organ failure score was correlated with change in muscle cross sectional
area, r = .23, p < .001. The authors concluded that skeletal muscle wasting occurred early and
rapidly in critically ill patients and appeared to be due to both decreased synthesis and increased
muscle breakdown and was associated with organ failure.
Gruther et al35 conducted a prospective observational study on 125 ICU patients. They
performed ultrasound measurements of the rectus femoris and vastus intermedius muscles and
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estimated muscle layer thickness (MLT). They were interested in identifying muscle wasting in
ICU patients and whether there was a relationship between muscle and length of stay (LOS).
They observed a significant negative correlation between admission MLT and LOS, p = .005.
Additionally, they were able to describe muscle wasting using a logarithmic function.
These studies lay the foundation for the growing understanding of the negative outcomes
associated with low muscle mass. Outcomes of increased mortality, longer LOS, greater
readmission rates and increased disease severity have all been demonstrated. Identifying low
muscularity and changes in lean body mass are then essential for the provision of prompt,
individualized nutritional therapy and mitigating adverse outcomes.43 The key step for the
practitioner thus lies in how to easily identify these at-risk patients with low muscularity in the
hospital setting.

Methods of measuring muscularity in hospitalized patients
Relying on body weight or body mass index (BMI) will fail to identify those with altered
body composition, particularly in those who are obese with low muscularity.43 The assessment of
muscle loss is now considered to be a key component of nutrition status.31,44 Although the
clinician may attempt to identify loss of muscle mass through the use of a nutrition focused
physical exam or anthropometric measurements, it remains a subjective assessment.31,45 Lean
tissue loss may occur prior to weight loss and may be difficult to discern with visual techniques
when there are concomitant changes in fat mass or extracellular water.44 More sensitive body
composition technologies and techniques are available to objectively measure or estimate lean
body mass.43,44,46,47 These techniques are gaining in acceptance and becoming more readily
available for use in the hospitalized patient. The most commonly used methods to evaluate body
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composition and muscle mass include computed tomography (CT), dual energy x-ray
absorptiometry (DEXA), bioelectrical impendence analysis (BIA) and ultrasound (US).43,44,46,47
Recent guidelines are available to aid the clinician in understanding the validity of some of these
various measurements.46
Studies which have examined the relationship between muscle mass and outcomes have
generally relied on CT scans to identify patients with low muscularity.43,44,47 CT scans use highdose radiation to produce cross-sectional images of organs, skeletal muscle, adipose tissue and
bone. Several computer programs are available to then analyze the images and make
determinants of body composition.43,47 CT scan measurements at the mid-lumbar, L3, vertebral
slice has been used to predict body fat and fat free mass. Cut-off points for low muscularity have
been established and thus are considered to provide reference measurements of body
composition.43 Although utilizing CT scans to measure muscle mass is considered a gold
standard, it is not always practical.43,44,47 As CT scans expose the patient to a high dose of
radiation, they are not ordered for the purpose of the nutrition assessment. Rather, their
nutritional use is limited to those patients who underwent CT scans as part of their medical
treatment. Short comings of relying on CT scans are that not all patients undergo CT scans early
enough or frequently enough to be useful in identifying malnutrition, muscle loss or sarcopenia.
These scans also require that the patient physically go to the radiology department which may be
precluded in the unstable patient. Importantly, measurements of muscle mass are not routinely
reported as part of CT scan results and these measurements require specialists trained in
measuring muscle and body compartments.43,44,47
Alternative methods for identifying low muscularity exist, although these have
limitations as well.19,44,46–48 DEXA uses much lower doses of radiation and relies on measured
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changes in x-ray attenuation to estimate body composition. As DEXA imaging is safer, it has
been utilized to develop normal body composition data which has been extrapolated to develop
reference values.47 DEXA has been found to be a valid technology to assess fat mass in adults,
however studies validating lean mass are lacking.46 DEXA can provide a measure of
appendicular lean mass, which is considered an indicator of muscle mass although hydration
levels can impact soft tissue readings.19,48 Currently there is a lack of studies using DEXA in the
inpatient setting and it may not be readily accessible in a variety of clinical settings.19 Lastly,
most DEXA imaging currently done only encompasses the lumbar or femoral regions and thus
does not include areas needed for the assessment of lean tissue. Whole body DEXA imaging for
body composition analysis will have additional costs associated and will require trained
personnel to read and interpret the results.46
Bioelectrical impendence analysis (BIA) uses low amplitude electrical current to
characterize the conductive and non-conductive fluids of the body. Fat and bone are poor
conductors of electrical currents compared to water, muscle and blood which are excellent
conductors. Electrodes placed on the body can measure the opposition to an electrical current
through the body tissues which can then be used to estimate total body water and body
composition.44,46 Advantages to the use of BIA for analysis of body composition include that it is
inexpensive, portable, non-invasive and the measurements can be performed relatively quickly.
BIA has several drawbacks of which the clinician should be aware of. BIA does not directly
measure body composition. However, it provides indirect estimates based on manufacturer
specific regression models. These models rely on several key assumptions which include that the
body is comprised of 5 cylinders of uniform cross-sectional area. This assumption may be
violated in those who are obese, have had an amputation or have shorter or longer than average
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limbs. BIA accuracy has also been found to be affected by adiposity, fluid and electrolyte status,
skin temperature and ambient temperature.43,44,46–48 Importantly, regression equations have been
generally derived from healthy, normal weight ambulatory patients. The assumptions of these
equations may not be true in the critically ill patient with alterations in intracellular and
extracellular compartments or in disease states which are characterized by expansion of
extracellular water.43 BIA has also been found to be unreliable in patients receiving electrolyte
containing intravenous fluids as the measurement appears to be affected by the ion content of the
fluid.49 It is currently unclear how long it takes to achieve ionic equilibrium after intravenous
administration of fluids, thus recommendations for appropriate timing of BIA measurements in
those hospitalized who require intravenous fluids cannot be made.49 For BIA to become more
reliable in the acute care setting, resolution of these issues and the development and validation of
accurate algorithms in the critically ill or hospitalized patients will be required.19,43,46,49
Ultrasound imaging of muscles utilizes high frequency soundwaves to produce images
based on the amplitude of the reflected soundwaves.43,46,47,50 US has been used to assess body
composition including visceral and subcutaneous adiposity and skeletal muscle. It has the
advantage of examining individual muscle groups and examining both muscle quantity and
quality through measures such as muscle thickness, cross sectional area and echogenicity.
Muscle thickness can be measured at multiple sites and equations have been proposed to predict
fat-free mass or skeletal muscle mass.44 These measurements have been used to identify
sarcopenia, malnutrition and muscle loss. The most commonly measured muscle in the critical
care setting has been the quadriceps as it is readily accessible and has easy to identify fascial
borders. US of the quadriceps has been used to predict whole body muscle mass and this
technique has been shown to provide reasonable estimates of muscle mass compared to other
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reference techniques.47,51 Musculoskeletal US is gaining in popularity, as it is less expensive, less
invasive and more portable compared to CT scans. These advantages allow the clinician to
obtain repeat measures and follow changes in muscle mass. For US use to become more widely
accepted, expert consensus on choice of muscle groups or anatomic site, degree of compression
and use of muscle thickness or cross-sectional area as the measurement standard will need to be
determined.52,53 Lastly, although sarcopenic cut-offs have been proposed to identify low
muscularity, further validation is required.35,43,46,47,50

Using creatinine to evaluate muscularity in hospitalized patients
Although these measurement techniques can provide valuable information, disadvantages
of cost, exposure to radiation, lack of standardization of procedures, need to transport the patient
to the radiology department, lack of mathematical models for specific patient populations, lack
of trained personnel and limited access to techniques and equipment will likely make these
measurements infrequently available to the average clinician.54 A widely available and longaccepted method for evaluating muscularity is by use of plasma creatinine levels and the 24-hour
urinary creatinine excretion method.54–57 Plasma creatinine levels and measurement of 24-hour
urinary creatinine excretion provide viable alternatives and avoid the disadvantages that occur
with the other measurement techniques.
Creatine is a nitrogenous organic compound which participates in cellular energy
metabolism and is found primarily in muscle. Creatine production requires several steps. The
first step involves the synthesis of guanidoacetate from glycine and arginine and requires the rate
limiting enzyme glycine amidinotransferase in the kidney.55,58 Then creatine is formed by the
transfer of s-methyl group from S-adenosylmethionine to guanidoacetate in the liver. This step is
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irreversible and not rate limiting. This synthesized creatine is then released into the circulation
where the next step is active uptake against a concentration gradient by muscle. This active
uptake of creatine results in the replacement of about 2% of the total amount of creatine in
muscle each day. As creatine uptake by muscles is relatively complete, blood levels remain low.
Within the muscle, creatine exists in two forms, creatine and creatine phosphate. Creatine is
continuously dehydrated by a nonenzymatic reaction to creatinine at a constant turnover rate.57,58
Once formed, creatinine then diffuses from the cell, is transported by the blood and ultimately
appears in the urine after glomerular filtration. In the healthy state and on a stable diet, creatinine
output is constant on a day to day basis for the individual.55,58
Creatinine is the sole metabolite of creatine and once formed undergoes renal excretion at
a constant rate.55 Since 98% of creatine is located in striated muscle, skeletal and cardiac muscle,
the amount of creatinine produced by the body varies directly and proportionally with the muscle
mass. It has been identified that 17.9g of muscle produces 1g of urinary creatinine every 24
hours, thus muscle mass can be predicted from 24-hour urinary creatinine excretion.56
Additionally, since muscle creatinine concentration is 3-5g/kg of wet fat-free tissue, muscle mass
can be reliably estimated.57 Due to these well identified processes and relationships, evaluation
of serum creatinine levels and urinary creatinine excretion can be used to estimate muscle mass
by validated equations.54,55 The ratio of total body muscle mass and 24-hour urinary creatinine
excretion approximates a constant commonly referred to as the creatinine equivalence.54
Researchers have confirmed strong correlations between plasma creatinine levels or
urinary excretion of creatinine and lean body mass. Schutte et al56 observed that total plasma
creatinine is a linear function of striated muscle mass and the two variables are strongly
correlated. They observed that plasma creatinine and urinary creatinine excretion were also
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strongly correlated, r = .82, p < .001, and that plasma creatinine was strongly correlated with
lean body mass, r = .72, p < .001.56 Urinary excretion of creatinine has also independently been
found to be strongly correlated, r = .98, with LBM as measure by K40 counting.59 Welle et al60
also demonstrated that creatinine excretion was closely associated, r = .93, with LBM as
determined by K40 counting and that the relationship was not affected by age or sex. Urinary
creatinine excretion was also found to be highly correlated with fat-free mass (FFM) as measured
by densitometry and deuterium dilution, r = .89, p < .001 and considered a good predictor of
FFM.61 Heymsfield et al55 demonstrated that muscle mass, as estimated from mid-arm muscle
area calculated from arm circumference and triceps skinfold, was strongly correlated with
urinary creatinine excretion, r = .94, p < .001.
Proctor et al62 compared DEXA and urinary creatinine excretion and compared those
methods to known standards of underwater weighing and total body water as estimated with
deuterium oxide dilution. They found that DEXA and urinary creatinine excretion did not detect
similar differences in total body skeletal muscle mass as a function of age. DEXA was not as
sensitive as urinary creatinine in identifying age related changes in muscle mass and that the
disparity between the two methods was accounted for by differences in total body water. They
observed that the creatinine excretion method provided a better estimate of age-related muscle
loss than DEXA and that the decline in muscle strength observed with the older subjects
corresponded with declines in muscle mass. Higher DEXA-based muscle mass estimates in older
subjects appeared to be due to age-related increases in body water content which in turn was
overestimated as lean tissue by DEXA.62
The clinician should be aware of certain metabolic or medical conditions that can alter
creatinine output and in those instances, creatinine should not be used to estimate muscle mass.
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Factors that can lead to elevated plasma creatinine concentration render the results unreliable and
include muscle injury, intense exercise and kidney disease.55,56 Renal disease, which results in
declines in glomerular filtration rate, will impact creatinine excretion. As glomerular filtration
falls, urinary creatinine excretion falls, and the creatinine output is no longer proportional to
muscle mass.55
Lastly, nutritional intake may affect creatine production and creatinine excretion and may
make results more difficult to interpret.55 Urinary creatinine excretion is influenced by three
dietary constituents: protein, creatine, and creatinine. Dietary protein is the main source of the
amino acid precursors of creatine and the level of protein intake has been noted to have a small
effect on urinary creatinine excretion. Providing nutrition supplements with increased amounts of
arginine and glycine, the two dietary amino acid precursors of creatine, may enhance
transamidinase activity and result in higher creatine production. Dietary creatine intake, from
meat, increases the size of the creatine pool which then proportionally increases the output of
creatinine in the urine. Therefore, when using creatinine excretion to assess muscle mass it is
important to control as many of these dietary factors as possible.55
Due to the correlation between plasma creatinine levels, urinary creatinine excretion and
muscle mass, low plasma creatinine levels and low urinary creatinine output can be considered a
marker of diminished muscle mass.20,56 This simple and inexpensive method to identify low
muscularity allows assessment without relying on more complex techniques such as CT scans or
DEXA.54,60 Perhaps more importantly, creatinine excretion originates from metabolically active
muscle cell mass which may have significant implications and advantages over other estimates
of muscle mass.62
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The relationship between creatinine and outcomes
Researchers have sought to examine the relationship between low plasma creatinine
concentration or low urinary creatinine excretion and outcomes. Udy et al63 conducted a large
retrospective study of over 1 million patients admitted to 175 ICUs across Australian and New
Zealand. They stratified patients based on their plasma creatinine concentration measured within
the first 24 hours of admission. They observed the highest in-hospital mortality in those with the
lowest creatinine levels, adjusted OR = 2.03, 95% CI 1.86-2.21 and that this was greater than for
those with elevated creatinine levels, adjusted OR = 1.60, 95% CI 1.55-1.66. Additionally, they
observed this relationship between in-hospital mortality and plasma creatinine levels across all
BMI categories.
Cartin-Ceba et al64 had previously conducted a retrospective study of 11,291 ICU patients
and examined the association between baseline plasma creatinine measured on admission and
hospital mortality. For purposes of analysis, they stratified patients into one of four plasma
creatinine levels, very low creatinine ≤ 0.6mg/dL, low creatinine 0.6-0.8 mg/dl, normal 0.91.4mg/dL and high >1.4mg/dL. They observed a U-shaped curve with both low and high
creatinine levels associated with unadjusted in-hospital mortality. A similar relationship was
observed for ICU length of stay. After multivariate logistic regression analysis was used to
control for BMI, age and gender, low baseline creatinine was associated with increased mortality
in a dose response manner, OR = 2.59, 95% CI, 1.82-3.61, for creatinine ≤ 0.6mg/dL and OR =
1.28, 95% CI, 1.03-1.60, for creatinine 0.6-0.8mg/dL.
Thongprayoon et al65 conducted a broader study of 73,994 patients admitted to the
general hospital population to determine if creatinine level was associated with in-hospital
mortality or 1-year mortality. For analysis, baseline plasma creatine was categorized into one of
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7 groups. They observed the lowest mortality in those with baseline creatinine levels of 0.70.8mg/dL and a U-shaped distribution with the highest mortalities observed in the highest and
lowest levels of creatinine. The risk associated with the lowest creatinine level, OR = 3.29, 95%
CI, 2.08-5.00, was greater than the risk associated with the highest creatinine level, OR = 2.56,
95% CI, 2.07-3.17. This association remained statistically significant even after adjusting for
BMI. Similar findings were observed for 1-year mortality, with patients with the lowest and
highest creatinine levels, experiencing the greatest mortality. They concluded that low plasma
creatinine value at hospital admission has important prognostic importance for patient outcomes
and appears to be a better surrogate marker for low muscle mass than BMI.65
Hessels et al66 examined the relationship between urinary creatinine excretion (UCE) and
mortality in 6151 ICU patients who had 24-hour urine collections within the first 3 days of ICU
admission. For purposes of analysis UCE was stratified into sex specific quintiles. They
observed that in-hospital mortality decreased for sex-specific quintiles of UCE, from 31% in the
lowest to 9% in the highest quintile, p < .001 of urinary creatinine excretion. In multivariable
logistic regression analysis with sex specific quintiles of UCE, they observed a 2.4 times increase
risk of in-hospital mortality in the lowest quintile compared to the highest, OR = 2.56, 95% CI
1.96-3.34, p < .001. In multivariable logistic regression analysis, UCE expressed as a continuous
variable was found to be inversely associated with in-hospital mortality, with every 5mmol/24
hour decrease in UCE, OR= 1.18, 95% CI 1.66-1.97, p < .001. Creatinine excretion additionally
had the advantage of not being affected by edema, common in the ICU setting, which confounds
weight, BMI and anthropometric measures.66
Khan et al67 utilized UCE to identify skeletal muscle loss in critically ill patients who
required ICU readmission. Using UCE to estimate skeletal muscle mass, they identified a >47%
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reduction in skeletal muscle mass from the first to second ICU stay. All patients in their series
met definition for sarcopenia based on muscle mass and all unfortunately expired.
UCE has also been associated with poor outcomes in specific disease states. For example,
ter Maaten et al68 examined 120 clinically stable outpatients with congestive heart failure and
sought to determine if a relationship existed between UCE and death, myocardial infarction or
heart failure hospitalization. They observed that patients in the lowest tertile of UCE experienced
the worst clinical outcomes and that low UCE was associated with more severe heart failure.
These studies demonstrate the strong relationship that has been identified between plasma
creatinine levels or UCE and mortality and other outcomes. Plasma creatinine levels and UCE
also appear to be strong predictors of poor outcomes independent of BMI. These represent
relevant biomarkers to aid the clinician in risk stratification and identifying those with low
muscularity who are at the greatest nutritional risk.

The Creatinine Height Index
Although advanced malnutrition or significant loss of muscle mass may be easy to
identify via nutrition focused physical exam, for the hospitalized patient, the detection of less
visually obvious or more subtle cases is key to prompt nutrition intervention and mitigation of
poor outcomes and may single out those patients most likely to benefit from aggressive nutrition.
The creatinine height index (CHI), initially developed for children and then later modified for
use in adults, has been used for over 40 years. The CHI is a simple method to assess degree of
muscle mass deficit and can be thought of as a combined anthropometric and biochemical
measure.69–72 The CHI utilizes the principles of the relationship between UCE and muscle mass
and is defined as the observed 24-hour urinary creatinine excretion divided by the amount
expected in normal subjects of the same sex and height expressed as a percentage.69–71 Ideal body
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weight, based on height and gender, when multiplied by the standard creatinine coefficient,
milligrams of creatinine excreted per day per kilogram body weight, provides the expected
amount of creatinine excretion per day. Normal values of UCE by gender and for various
heights have been determined and published.69
The CHI is thus considered a marker of muscularity and used to detect protein
depletion.57,69–71 A CHI <60% of predicted is defined as severe loss of muscle and related to a
midarm muscle circumference of <10th percentile, between 60-80% of predicted as moderate
loss, 80-90% as mild loss and >90% as normal.70,72 CHI has been observed to be more sensitive
than other measures of nutrition status.69 An advantage of CHI is that it is not affected by weight,
edema or obesity and its value is not altered by the inflammatory response like albumin or
prealbumin.73 Although less commonly used today, CHI is considered a well-established
standard in evaluating malnutrition and muscularity.57,70–72,74–76

The relationship between CHI and outcomes:
CHI, as a surrogate for LBM, has been examined in a variety of settings and correlated to
outcomes. Datta et al73 studied 167 patients on ventilators in a long-term acute care facility. They
obtained CHI and a variety of other nutritional indices in these patients and then followed them
to assess ability to wean from the ventilator. Patients were stratified by the CHI into normal to
mild malnutrition, CHI >81%, moderate malnutrition, CHI 61-80%, severe malnutrition, CHI
41-60%, and very severe malnutrition, CHI <40%. They observed that total serum protein,
hemoglobin and CHI were significant predictors for successful weaning, with CHI having a
stronger statistically significant effect on successful weaning and survival than any other
variable, p = .0002.
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Schwebel et al77 examined CHI and percent Ideal Body Weight (%IBW) in a group of
patients awaiting lung transplantation. They observed that decreased LBM, as identified by CHI,
was not always related to %IBW and that low CHI was strongly related to degree of hypoxemia
and death while awaiting transplant, p < .03. In those that received a transplant, low CHI was
also found to be related to prolonged time on vent, p < .05, and ICU LOS, p < .001.
Medhat et al78 utilized CHI along with serum albumin level, mid-arm circumference,
triceps skinfold, mid-arm muscle circumference, BMI and Subjective Global Assessment (SGA)
to evaluate 103 patients with cirrhosis. The researchers observed that SGA identified
malnutrition in 92.2% of patients, CHI identified malnutrition in 89.2%, and mid-Arm muscle
circumference identified malnutrition in 86.4% of patients. CHI was noted to significantly fall
with progression of cirrhosis from Child Pugh Score A, to B to C, p < .001. Of note, no patient
was identified as being underweight by BMI, with 23% being normal weight and 77% being
overweight or obese.
Apelgren et al79 examined a variety of commonly available nutritional parameters,
including albumin, weight for height, and CHI, in a small group of critically ill veterans. They
observed that both albumin and CHI had weak negative correlations with duration of ICU LOS, r
= -.36 and -.46 respectively. Additionally, CHI was statistically higher in survivors compared to
non-survivors, p < .05.79

Limitations of using UCE or CHI in the hospitalized patient:
A limitation in the use of urinary creatinine excretion or CHI to assess muscularity is the
need for an accurate 24-hour urine collection.80–82 Twenty-four-hour urine collections, in the
hospital setting, can be fraught with problems. These include inconvenience on the part of
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nursing or the patient, inaccurate timing and incomplete collections for those patients without
urinary catheters. Inaccurate timing refers to when the collection extends beyond the 24-hour
mark and thus will over-represent the amount excreted in 24-hours. Incomplete collections may
occur due to patient incontinence, nursing accidently discarding part of the sample, or for
patients without urinary catheters, forgetting and using the restroom rather than collecting the
full sample.80–82 Although spot urine samples, or time frames less than 24 hours have been
utilized, difficulties with reliability persist, likely due to diurnal variations in nitrogen excretion,
which have resulted in underestimating actual excretion.80–82

Novel solutions to limitations:
To allow wider application of CHI within the clinical setting, it has been proposed that in
patients with normal renal function, the urinary creatinine excretion may be estimated from the
plasma creatinine level.83 The proposed estimation is accomplished with the following equation:
CC = UV/P, in which CC is normal creatinine clearance of 80ml/minute, UV represents 24-hour
urine creatinine, P represents plasma creatinine concentration and one solves for UV. CHI would
then be calculated from the estimated urinary creatinine excretion.83 This proposed manipulation
has the additional benefit, in those with stable renal function, of allowing retrospective
estimation of CHI and muscularity to examine changes over the course of the hospitalization.83-85
The estimation of 24-hour urinary creatinine excretion from plasma creatinine level and
subsequent estimation of CHI, although having the potential to be clinically useful, has not been
modeled or validated to date.
Currently our understanding of protein requirements for critically ill, hospitalized adults
and for specific subgroups is inadequate. It appears unrealistic to define protein requirements for
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different diagnostic groups at different stages of illness, with varying degrees of nutrition risk
and underlying muscularity with one set of recommendations.13,17,83 It is important to further
identify personalized factors, such as low muscle mass and degree of metabolic stress, to allow
the clinician to individualize nutrient intake and identify those patients most in need of prompt
adequate protein intake.13,17,83 Although accurate methods exist to detect low muscularity, the
identification of readily available, non-invasive biomarkers would allow rapid screening of the
majority of hospital admissions and provide a potential method for subsequent longitudinal
follow up.57
As no readily available biomarkers that screen for low muscularity exist, this project
attempted to fill the existing gap by exploring if a robust model could be identified that predicted
UCE from plasma creatinine level or other patient variables. This project also explored if model
derived UCE and subsequent estimated CHI was related to patient outcomes and other
commonly assessed measures of nutrition and metabolic stress.

Chapter 2: Theoretical Framework

Modeling
Mathematical modeling is the process of creating a mathematical model from a data set
and is a method in which mathematical terms are used to represent the behavior of real-world
functions, and describe their aspects, their interaction and dynamics. In broad terms, models are
developed to describe what is seen, explain why results occurred and to predict future results and
outcomes.86–88 Models are a representation of reality in simplified forms. Mathematical models
are used to develop scientific understanding, test the effect of changes in a system and aid in
decision making. Mathematical modeling is routinely used throughout the disciplines of
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medicine and health for widely ranging purposes such as drug metabolism and dosing89,
antibiotic resistance90, disease diagnosis91,92, simulation and prediction of organ damage
associated with drug or alcohol consumption93,94, infection control and infectious
transmission95,96 and estimates of mortality97 to name a few. Nutrition professionals may be
familiar with applications of modeling. The Prognostic Nutritional Index uses mathematical
modeling to predict operative morbidity or mortality based off 4 nutrition parameters and the
Nutrition Risk Index uses modeling to predict risk of post-operative complications based off of 2
nutrition parameters.98–100
To better discuss models, it can be considered helpful to identify classification categories
between types of models. Models may be classified according to their structure and reflect their
output and how they are used. A common classification method is to classify a model as
deterministic or stochastic.

Deterministic Models
Deterministic models are designed to have precise outcomes through known relationships
and exclude random variation. Thus, a deterministic model will always produce the exact same
output when starting from a given initial state because the output of the model is fully
determined by parameter values and the initial conditions of the system. It predicts outcomes
with 100% certainty. Deterministic modeling is used when no randomness is involved in the
development of future states of the system.86–88 For example, when using linear regression, if
deterministic relationships exist between variables, one can predict with 100% certainty where
the y-value will be based on the x-value. Ordinary differential equations and regression equations
are used in deterministic modeling using powerful computer programs.86–88,101
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An example of deterministic modeling is one of the many models that was published
during the early days of the Covid-19 pandemic.102 As so little was known about the virus,
researchers sought to use modeling to compute the infected population and number of casualties.
Carcione and colleagues102 used a version of the Susceptible-Exposed-Infectious-Removed
(SEIR) model to describe the spread of the virus and compute the number of infected, recovered
and dead individuals on the basis of number of contacts, probability of disease transmission,
incubation period, recovery rate and fatality rate in a region of Northern Italy. The
SEIR model predicts a peak of infected and dead as a function of time, assumes births and
natural deaths are balanced, and that population decreases due to the disease are dictated by the
fatality rate of the disease. The parameters of the SEIR model are per capita birth rate, per capita
natural death rate, virus induced average fatality rate, probability of disease transmission, rate of
progression from exposed to infectious, and recovery rate of infectious individuals. SEIR is a
system of non-linear ordinary differential equations which are solved numerically using
computer programs. Specific differential equations exist which govern 4 population classes of
susceptible, exposed, infected-infectious and recovered. The researchers first solved the
differential equations using published Covid-19 data from Hong Kong and Singapore to develop
a Covid-19 model.
Next, they then applied the model to census and health data available from the Lombardy
region in Italy. Use of the model allowed them to predict the number of infected individuals, the
number who would require ICU admission, the day the peak of infected would occur on and
predicted fatality rates. Using the model, they predicted that in less than three weeks the
healthcare system in the region would be overwhelmed. The authors conclude that simulating the
process of the infection is key to preparedness and to applying control measures.102
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Deterministic models are not as commonly used in the field of medicine because
deterministic modeling only allows the use of integers and does not allow for the random
fluctuation that occurs within biological systems. Deterministic models are likely to have less
clinical value because clinical cohorts have random variation that are not necessarily found in
research settings.86,101 Due to this, attention will be focused on stochastic models.

Stochastic models
Stochastic models are used to predict the distribution of possible outcomes and are based
on random approaches. Stochastic models assume that the dynamics of the system being studied
are partly driven by random fluctuations, such as blood glucose levels throughout the day, and
because of this, the same set of parameter values and initial conditions can lead to different
outcomes.86–88 Stochastic modeling in medicine considers that each biologic process is a random
event that can take place with a certain probability.101,103 Stochastic modeling is conducted with
computer programs utilizing probabilistic equations and analysis of variance.87,101

Steps of Model Building
The steps to modeling can be roughly thought of as follows.88,101,104 First, the investigator
needs to identify if the current problem or question is amendable to mathematical modeling.
Second, a data source needs to be identified which can be used for modeling purposes. In
medical research this data may come from the electronic medical record (EMR), FDA drug
databases or from state or federal agencies such as the health department or CDC to name a few
examples.
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Next, the obtained data set is randomly divided into sets. A common approach is to
divide the data into three subsets. A training set, to build the model, contains approximately 80%
of the data. A test set of 10% of the data is set aside to select the best model from among the
models developed. The validation set, which contains the remaining 10% of the data is then set
aside for validation purposes. Ideally the validation set is not used in the development of the
model and saved specifically for validation.86
The next step is to build the model using the training data set and several accepted
mathematical equations, identifying variables which continue to improve the model. When no
previous or limited knowledge exists that can adequately describe a relationship between
variables of interest, the researcher generally starts with a body of data and attempts to fit
equations to it. The most commonly used algorithms to accomplish this are support vector
analysis, linear regression, logistic regression and linear discriminant analysis.101 When
modelling the data using the training set, the inputs consist of the input predictor variables and
the outputs are the result after application of the model. Commonly used methods to create this
transformation include sum of squared residuals, which is an aggregate measure of total
variability, maximum likelihood estimation, a method of estimating the parameters of a
probability distribution, or maximizing the constraining hyperplane, also called support vector
machines (SVM). SVM, considered a non-probabilistic binary linear classifier, uses the training
data set and identifies the variables as belonging to one of two categories, it then builds a model
that maximizes the width of the gap between the two and then assigns new data to one or the
other category.101
After models are identified, the investigator must select the one that best describes or fits
the data. Thus, the next step in the process is to take the second set of data, the test set, and
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decide which of the developed models works best by some measure of goodness. This is
generally accomplished by identifying the model with the smallest mean squared error between
predicted and measured data.86
The last step is model validation which is performed with the remaining 10% of data
partitioned aside for this purpose. Validation is the objective method that establishes the
generalizability of the model and tests it against observations from the system it is intended to
represent. A model should be validated for both intrinsic bias and extrinsic variance. The most
common way to validate the model is to measure the mean squared error from the residuals as
the model is applied with the difference between the observed and predicted values providing a
measure of accuracy.86,104

Development of a stochastic model
An example of stochastic modeling is the development of the NUTRIC risk assessment
tool.105 Heyland and colleagues postulated that not all critically ill patients have the same
nutrition risk in that some benefit from nutrition intervention more than others. Their goal was to
identify variables that would quantify the risk of a patient developing adverse events. Based on
previously published research, they postulated that potential variables were age, the Acute
Physiology and Chronic Health Evaluation (APACHE II) score, the Sequential Organ Failure
Assessment (SOFA) score, interleukin-6 (IL-6), c-reactive protein, co-morbid illness, weight loss
over the last 6 months, BMI <20, decreased oral intake over the previous week and pre-ICU
hospital admission. The outcomes selected were ICU length of stay, 28-day mortality and
ventilator free days within 28 days. The data set identified was the EMR from a convenience
sample of 597 patients admitted to 3 tertiary care medical-surgical ICUs.
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The investigators first validated the candidate variables by describing their association
with 28-day mortality with chi-squared tests, Wilcoxon rank-sum tests, and Spearman correlation
coefficients. Based on results and an additional sensitivity analysis, variables of oral intake,
weight loss, BMI and c-reactive protein were excluded from further models. The remaining
candidate variables were each fit as categorical predictors in separate single predictor logistic
regression models predicting 28-day mortality. The parameters for each logistic regression model
estimated the log of the odds ratio for each category of the variable compared to the lowest risk
category. These parameters were rounded to whole numbers to provide the points used in the
NUTRIC score. Variables were excluded if the inclusion in the NUTRIC score did not improve
the scores ability to predict 28-day mortality. Additionally, using a multivariable fractional
polynomial approach yielded a similar model with no improvement in performance. The final
variables remaining were age, APACHE II score, SOFA score, number of co-morbidities, days
from hospitalization to ICU admission and IL-6 level. Each variable remained independently
statistically significant in the multivariable logistic model.
Validation of the model was performed by evaluating the quality of the NUTRIC model
to predict 28-day mortality on a set of data. Model discrimination was assessed by the C-statistic
derived from calculating the area under the receiving operating characteristic curve and the
generalized max-rescaled R-squared statistic. Goodness of fit was assessed by comparing the
predicted and actual mortality by the Hosmer-Lemeshow goodness of fit test.
Lastly, in a subset of 211 patients who had dietary intake data, the researchers examined
if the NUTRIC score modified the association between intake and 28-day mortality. Logistic
regression with nutritional intake, NUTRIC score and their product as continuous independent
variables was used to generate a plot of association between intake and mortality by NUTRIC
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score. They demonstrated that the association between risk score and mortality is attenuated in
patients who meet calorie targets. The authors concluded that they believe they have identified a
novel scoring tool, using a variety of mathematical techniques, to help identify which patient
would benefit most from aggressive nutrition intervention.105

Model Application for Current Problem
As low muscularity has been strongly associated with outcomes, it is important to be able
to promptly and easily identify those patients. Muscle measurements using techniques such as
CT scans exist, however disadvantages of cost, exposure to radiation, lack of standardization of
procedures, and limited access to techniques, trained radiologists and equipment will likely make
these measurements infrequently available to the average clinician.54 The nutrition focused
physical exam remains a subjective measure and anthropometric measurements of mid-arm
circumference and triceps skinfold are impractical for screening all new admissions. The
identification of readily available, non-invasive biomarkers or measures would allow rapid
screening of the majority of hospital admissions and provide a potential method for subsequent
longitudinal follow up.57 UCE and subsequent estimation of CHI have been strongly associated
with muscularity and outcomes, however require a 24-hour urine collection. The postulation that
UCE may be estimated from plasma creatinine or other patient variables would avoid the need
for a 24-hour urine collection and is uniquely suited to mathematical modeling. The ability to
predict CHI from model derived UCE may have clinical utility to become a quick screening tool
to identify low muscularity, malnutrition and predict outcomes.
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Chapter 3: Methodology

Study Purpose
The purpose of the study was to develop a model to predict UCE from patient variables.
The study additionally sought to determine if application of this model, to predict UCE and
subsequent estimation of CHI, in a cohort of hospitalized veterans, was correlated with
outcomes.

Study Aims
The primary aim of this research was to determine if 24-hour UCE can be reliably
estimated from plasma creatinine or other patient variables by the development of a model and if
the model can be validated. The secondary aims were to determine if low muscularity based on
model derived CHI was correlated to low muscularity based on anthropometric measurements, to
describe the degree of low muscle mass observed and determine if model derived UCE and CHI
were associated with other assessment measures and outcomes in a cohort of hospitalized
veterans. This study was reviewed and approved by the James A. Haley Veterans Hospital
Research and Development Committee and the University of South Florida IRB and determined
to meet criteria for an exempt study.

Hypothesis
Phase 1: H𝜃 There is no relationship between patient variables and UCE.
Phase 2: H𝜃 There is no relationship between UCE, CHI and outcomes.

Objectives
1. To build a model to predict 24-hour UCE from plasma creatinine or other patient
variables using a large de-identified data set.
2. To validate the proposed model.
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3. In a subset of patients, who had anthropometric measurements obtained, explore how
well CHI, estimated from the model derived UCE, is associated with muscularity based
on anthropometric measurements
4. Apply the model retrospectively to 120 intensive care unit patients to predict 24-hour
UCE for each subject
5. Based on model derived 24-hour UCE, calculate CHI for the whole cohort and describe
prevalence of low muscularity in the cohort.
6. To explore if a relationship exists between CHI and the identification of malnutrition
using AND/ASPEN criteria
7. To explore if CHI is associated with outcomes of hospital LOS, ICU LOS, hospital
mortality, 6-month mortality, 30-day readmission or discharge location.
8. To explore if relationships exist between CHI and commonly collected assessment
parameters of albumin, prealbumin, c-reactive protein (CRP), NUTRIC score, APACHE
2 score and SOFA score.

Study design
Phase 1: Model Development Study Design
The first phase was the development of a model to predict 24-hour UCE from plasma
creatinine level or other candidate variables of plasma blood urea nitrogen, sodium, potassium,
glucose, chloride, carbon dioxide and magnesium and demographic variables of gender, age in
years, height in centimeters, weight in kilograms and presence of spinal cord injury or neurologic
disease. The model with the best R2 was examined for validation. Lastly, whether muscularity,
based on anthropometric measurements, was correlated to muscularity, based on model derived
CHI, was examined.
40

Phase 1: Study Participants and Sample Size
Eligible participants were veterans who received care at the James A. Haley Veterans
Hospital in Tampa Florida (JAHVA) who had 24-hour urine laboratory testing which included
creatinine excretion between 10/01/2016 to 09/30/2021. It was estimated that approximately 3001000 patients would be sufficient for model development.86

Phase 1: Data Collection
A data set was obtained from Data Analytics and Acquisition Services (DAAS) which
contained the laboratory, demographic and diagnosis variables of patients who received care at
JAHVA, and who had 24-hour UCE measured, between 10/01/2016 to 09/30/2021. Mid-arm
muscle circumference, triceps skinfold and mid-arm muscle area measurements were extracted
from the EMR in a subset of 44 patients who had anthropometric measurements obtained by
searching with the note title of “Nutrition Assessment”.

Phase 1: Statistical Methods
An initial test data set of 956 serum and urinary creatinine pairs was examined to identify
potential mathematical relationships. A scatter plot was generated and visually examined for
spline fitting. For plasma creatinine values greater than 5.0 mg/dL the relationship between
serum and urinary creatinine appeared random. For pairs with plasma creatinine levels between
1.5 and 5.0mg/dL, a linear relationship appears to emerge but with substantial scatter. For plasma
creatinine from 1.5mg/dL and below, a strong linear relationship was observed with a wide band
of scatter around a central line. Using the 448 urine and plasma creatinine pairs with plasma
creatinine of 1.5 or below, a regression analysis was run.
Next, additional patient input variables, readily available on admission, were added to
develop models and improve the overall predictability. Input variables included were age, height,
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weight, gender, serum urea nitrogen, glucose, sodium, potassium, chloride, carbon dioxide,
magnesium and presence of a spinal cord injury (SCI) as surrogates to account for total body
water, extracellular water and lean body mass. A data set of those patient variables for patients
who had UCE measured in the previous 5 years was obtained from DAAS. The data set of 1592
patients were reduced to 967 after patients with missing or incomplete data were excluded. The
subjects in the data set were 87.4% male and 12.6% female. For this step of model development,
a plasma creatinine of ≤ 1.2 mg/dL was considered normal as it reflects the hospital’s reference
interval.
Descriptive statistics were completed, and all variables were examined for skewness and
kurtosis. A correlation matrix was run and examined for multicollinearity. Age, weight, plasma
creatinine and plasma BUN were observed to be the least correlated with one another. Next, a
best fit regression was conducted which took every possible combination of variables and
examined the R2 for each regression equation. Using several mathematical and analytical
modeling approaches, including support vector analysis, linear regression and polynomial
regression, models were constructed. Using stepwise regression and backward elimination with
Alpha-to-remove at the 0.1 level, deleting input variables which were not significant, linear
regression models were produced. The amount of variance explained did not increase after input
of the four variables of age, weight, plasma creatinine and plasma BUN. To avoid overfitting,
further input variables were not included.
Where indicated, Box-Cox transformation, mathematical curve fitting, was performed to
test if transforming the outcome variable improves the model and to optimize the mean squared
error. Using Box-Cox transformation, the log of the outcome variable, which produced the
smallest mean squared error, was identified. For the final identified statistically significant
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multivariable models, each remaining input variable was found to be independently statistically
significant.
Next, the model with the smallest mean squared error between predicted UCE and
measured UCE, Model 3, was identified for validation. Validation was performed with two
approaches. First the model was validated using cross validation methodology in which the data
was randomly divided into 4 data sets. Then, using an additional set of 50 patients which were
not included in the model development, the model was tested for goodness of fit, predictive
performance and regression residual diagnostics.101 Statistical analyses for the development of
models were performed using Minitab, I., 2020. MINITAB, http://www.minitab.com/enUS/products/minitab/.
Lastly, in a subset of 44 subjects, with normal plasma creatinine and without the presence
of SCI, who had upper arm anthropometry measured, CHI was calculated from the Model 3
predicted UCE. A correlation matrix was run comparing CHI to arm circumference (AC), arm
muscle area (AMA) and arm muscle circumference (AMC).

Phase 2: Model Application Study Design
In the second phase, a retrospective review of the electronic medical records (EMR) of
ICU patients who received a complete nutrition assessment by the registered dietitian at the
JAHVA was conducted. Using patient data extracted from the EMR, Model 3 was applied to
estimate UCE and CHI for the cohort. Based on CHI, calculated from UCE, the prevalence of
low muscularity was described for the cohort.
Next, extracted data was examined to determine if UCE or CHI were clinically useful in
predicting the presence of malnutrition, or were associated with outcomes of hospital LOS, ICU
43

LOS, hospital mortality, discharge location, 6-month mortality and 30-day readmission in the
cohort. Lastly, extracted data was examined to determine if relationships exist between UCE and
CHI and patient variables of albumin, prealbumin, c-reactive protein, NUTRIC score, APACHE
2 score, and SOFA score.

Phase 2: Study Participants and Sample Size
Patients who were hospitalized at JAHVA between 1/1/2016 to 9/30/2021, who during
the course of their hospitalization required ICU admission, received full nutrition assessments
and who had plasma creatinine levels of 1.2 mg/dL or less on admission were considered for
inclusion. Patients were excluded if they were hospitalized < 72 hours, their admission plasma
creatinine was greater than 1.2 mg/dL, or if they had a medical condition that is associated with
muscle wasting such as spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis or
other neurological diseases. It was estimated, for analysis, that a sample size of 120 patients was
needed for a medium effect size, and an 𝛼 of 0.05.106,107

Phase 2: Data collection
Eligible patients were identified from the EMR by searching note titles of “Nutrition
Assessment”, with the location of one of the intensive care units between the dates of 1/1/2016 to
9/30/2021. Patients identified for potential inclusion had their EMR reviewed for eligibility. The
retrospective chart review began with those admitted 9/30/21 and proceeded backwards until 120
subjects that met criteria were reached. All data for Phase 2 was obtained and extracted from the
medical record. Data after extraction from the EMR was entered into a password protected
spreadsheet and de-identified upon entry.
All patients identified for inclusion in Phase 2 had the following extracted from the EMR
for the admission:
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•

age on admission

•

gender

•

reported race

•

height in centimeters

•

admission weight in kilograms

•

admission BMI

•

Primary and secondary medical diagnosis

•

date of hospital admission

•

date of ICU admission

•

date of ICU discharge

•

date of hospital discharge

•

admission plasma creatinine and blood urea nitrogen

•

albumin from date of nutrition assessment

•

pre-albumin from date of nutrition assessment

•

C-reactive protein from date of nutrition assessment

•

presence of malnutrition based on documentation in nutrition assessment

•

mortality during admission and up to 6 months after discharge

•

Discharge location

•

Readmission within 30-days of discharge

The following were calculated for each patient from extracted data:
•

ideal body weight (IBW)

•

Model 3 derived UCE
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•

CHI calculated from Model 3 derived UCE

•

APACHE 2 score

•

SOFA score

•

NUTRIC score

•

Hospital and ICU LOS

Model 3 was applied to each subject to predict UCE based on admission weight and
admission plasma creatinine and BUN. For patients with multiple ICU admissions during the
course of their hospital stay, all ICU days were added together to represent total ICU LOS.
Primary and secondary medical diagnosis were collected to calculate APACHE 2 and NUTRIC
scores. APACHE 2 and SOFA scores were based on the first ICU admission for those who had
multiple admissions. Discharge location was grouped as either discharge to home, skilled nursing
facility, long term acute care, hospice, transfer to another hospital for care not available at
JAHVA or not applicable for those that died during the admission. Degree of sarcopenia was
determined based on CHI and defined by the following cut-offs: >75% of expected as
normal/absent sarcopenia, <75-61% of expected as mild sarcopenia and <60% of expected as
severe sarcopenia. Death dates, even if they occurred outside of a hospitalization, are recorded in
the EMR as it serves as part of the veterans record of benefits.
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Phase 2: Statistical Methods
Descriptive statistics were calculated to describe characteristics of the cohort. Continuous
variables are reported as mean (± standard deviation) or median (25%-75% interquartile range
[IQR]) and categorical data are reported as counts and percentage. Between-group comparisons
for baseline characteristics and length of stay were analyzed using a 𝜒2 test for categorical
variables and Student t test or MANOVA for continuous variables as appropriate. A correlation
matrix was run for all predictor and outcome variables to identify possible relationships. Linear
regression analysis models, ANOVA and MANOVA as appropriate, were performed to assess
the association of UCE and CHI and outcomes and patient characteristics. Odds ratios were
calculated using 𝜒2 and logistic regression to examine relationships between CHI and outcomes.
For purposes of statistical analysis, CHI ≤60% was considered low and >60% was normal,
malnutrition was classified as present or not present, and mid-arm muscle area ≤ 25th percentile
was classified as low and > 25th percentile as normal. All tests for statistical significance were
two tailed and statistical significance was established at the threshold of p < .05. Missing data for
laboratory measures was managed by insertion of means, as missing data represented only 2-6%
of each measure. Statistical analyses were performed using IBM SPSS Statistics for Windows,
version 25.0 (Armonk, NY: IBM Corp; 2017).
Chapter 4: Results
This chapter will present the results of the data analysis for Phase 1 and Phase 2 of the
research study. First, the results of model development will be presented. This will include the
identification of several viable models. Next, the results of model validation will be presented.
This is then followed by results of the analysis of model derived output and correlation with
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known measures of muscularity. Next, the results of the application of the model to a cohort of
patients will be reported. Baseline demographics of the cohort will be presented and prevalence
of low muscularity and malnutrition for the cohort will be described. Lastly, the relationship
between model derived UCE and CHI and outcomes will be highlighted.
Phase 1

Model Building
An initial model was developed using only plasma and urinary creatinine pairs. Using the
448 urine and plasma creatinine pairs with plasma creatinine of 1.5 or below, it was identified
that serum creatinine was a significant predictor of UCE but only accounted for 5% of the
variability, R2 = .0549; p <.001, rendering it unsuitable to use for the practical prediction of
individual UCE values. Residual diagnostics were conducted and found to be normally
distributed.
After the additional patient input variables were added, the following linear regression
models were identified with potential utility for different patient populations (Table 2, Table 3,
Table 4). Gender is defined as 1 = male and 2 = female. SCI is defined as 1 = presence of SCI
and 2 = no SCI.
Model 1. For the general population with normal plasma creatinine:
Predicted Urinary Creatinine = 1426.93 – (262.82 x Gender) + (403.15 x SCI) – (20.47 x Age) +
(7.39 x Weight) – (66.23 x Plasma Creatinine), R2 = .4085, p < .001.
Model 2. For the general population with plasma creatinine >1.2mg/dL:
Predicted Urinary Creatinine^0.5 = 36.02 – (4.76 x Gender) + (7.12 x SCI) – (0.298 x Age) +
(0.12 x Weight) – (1.04 x Plasma Creatinine) – (0.02 x Plasma BUN) – (0.17 x Plasma
Potassium), R2 = .4051, p < .001. In which the predicted urinary creatinine is transformed by the
48

square root, the result of which is then squared to revert back to the original scale, to obtain the
final model predicted urinary creatinine.
Model 3. For patients without SCI and with a normal plasma creatinine:
Predicted Urinary Creatinine^0.833735 = 0 – (1.11 x Age) + (3.00 x Weight) + (231.92 x Plasma
Creatinine) – (2.59 x Plasma BUN), R2 = .9098, p < .001. In which the predicted urinary
creatinine is transformed, and the result of which is then reverted back to original scale, to obtain
the final model predicted urinary creatinine. Overall, Model 3 was found to be highly predictive
of UCE.
Table 2. Model 1 For Patients with or without SCI and Plasma Creatinine < 1.2 mg/dL
Constant
Gender
SCI
Age
Weight
Plasma
Creatinine

B
1426.93
-262.82
403.16
-20.47
7.39
-66.23

SE (B)
282.14
120.07
88.33
1.81
0.87
5.09

𝛽
-0.16
0.24
-0.44
0.30
-0.03

p
< .001
0.03
< .001
< .001
< .001
<.001

R2= .408, p < .001
Table 3. Model 2 For Patients with or without SCI and Plasma Creatinine >1.2 mg/dL

Constant
Gender
SCI
Age
Weight
Plasma
Creatinine
Plasma BUN
Plasma
Potassium
R2 = .405, p < .001

𝛽

B
36.02
-4.76
7.12
-0.30
0.12
-1.05

SE (B)
4.93
1.94
1.43
0.03
0.01
0.09

-0.001
0.003
-0.006
0.005
-0.008

p
< .001
.014
< .001
< .001
< .001
< .001

-0.02
-0.17

0.01
0.52

-0.0009
-0.0002

.16
.74
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Table 4. Model 3 For Patients without SCI and Plasma Creatinine < 1.2 mg/dL

Age
Weight
Plasma
Creatinine
Plasma BUN
2
R = .91, p <.001

B
-1.11
2.99
231.92

SE (B)
0.36
0.25
30.71

𝛽
-0.095
0.486
0.339

p
.002
< .001
< .001

-2.59

0.61

-0.196

< .001

Model Validation
Model 3 validation was conducted by two methods. First, cross validation was conducted
using the original data set. Four-fold cross validation resulted in R2 of .4171, .4485, .4488 and
.4488, all p < .001. Next, Model 3 was validated using a data set of 50 subjects, which were not
included in model development. Mean predicted UCE was 1019.46 mg ± 318.63 SD, and mean
measured UCE was 1033.04 mg ± 342.08 SD. Predicted and measured UCE were found to be
highly correlated, r = .716, p < .001. Linear regression analysis yielded R2 = .502, F = 50.478, p
< .001. Durbin-Watson statistic = 2.071 indicated no autocorrelation in the residuals of the
regression.

Relationship between model derived CHI and muscularity
In a subset of 44 subjects, with normal plasma creatinine and without the presence of
SCI, who had upper arm anthropometry measured, CHI was calculated from the Model 3
predicted UCE. A correlation matrix was run comparing CHI to arm circumference (AC), arm
muscle area (AMA) and arm muscle circumference (AMC). Model derived CHI was found to be
strongly correlated to AC, r (42) = .665, p < .001, AMA, r (42) = .551, p < .001, and AMC, r
(42) = .559, p < .001. Overall, CHI calculated from Model 3 predicted UCE was found to be
highly correlated with accepted measures of muscularity.
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Phase 2

Application of Model
A total of 191 medical records were retrospectively screened for inclusion. Forty-seven
were excluded due to admission plasma creatinine >1.2mg/dL and 24 were excluded due to
medical diagnosis which are associated with muscle wasting. A cohort of 120 patients had Model
3 applied and UCE and CHI estimated, demographic and outcome data collected and were
included in the final analysis.

Baseline demographics of study population
Baseline admission characteristics are presented on Table 5. All subjects were male. The
mean age for the cohort was 69.08 ± 8.7 years, mean height 176.4 ± 6.8 cm, mean weight 83.5
± 19.5 kg, mean BMI 26.9 ± 6.4 and mean IBW 73.8 ± 7.3 kg. Self-reported racial composition
of the cohort was 93 (77.5%) were white, 24 (20%) were black and 3 (2.5%) did not report race.
Admission laboratory values of the cohort were mean plasma creatinine 0.94 ± 0.17 mg/dL and
mean plasma BUN 15.6 ± 5.1 mg/dL.
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Table 5. Baseline Demographics
Characteristic

Whole Cohort
(n=120)
69.00 (65.00,73.00)

Subjects with CHI
≤ 60% (n=53)

Age, median (IQR),
years
Mean (SD)
Age, years
69.08 (8.75)
69.00 (9.24)
Height, cm
176.42 (6.77)
177.61 (6.98)
Weight, kg
83.50 (19.51)
69.93 (12.86)
BMI
26.90 (6.39)
22.11 (3.78)
Plasma BUN, gm/dL
15.64 (5.05)
15.24 (5.13)
Plasma Creatinine,
0.94 (0.17)
0.83 (0.12)
mg/dL
Albumin, gm/dL
2.55 (0.58)
2.42 (0.48)
Prealbumin, mg/dL
10.48 (5.67)
9.00 (4.18)
CRP, mg/L
9.46 (7.69)
9.25 (7.69)
APACHE Score
15.93 (4.88)
16.09 (5.29)
SOFA Score
3.59 (2.64)
3.57 (2.49)
NUTRIC Score
3.63 (1.39)
3.62 (1.47)
CHI = creatinine height index; * p < .05; ** p < .01; *** p < .001

Subjects with CHI
>60% (n=67)

69.13 (8.41)
175.48 (6.51)
94.24 (17.06) ***
30.69 (5.42) ***
15.96 (5.00)
1.03 (0.14) ***
2.65 (0.63) *
11.69 (6.42) **
9.63 (7.76)
15.81 (4.57)
3.61 (2.76)
3.64 (1.33)

The mean severity of illness scores and nutrition screening scores for the cohort were
APACHE II 15.93 ± 4.88, SOFA score 3.59 ± 2.64, and NUTRIC score 3.63± 1.39. The mean
serum protein levels, on the day of the nutrition assessment, were Albumin 2.55 ± 0.58 g/dL,
Prealbumin 10.48 ± 5.66 mg/dL and CRP 9.46 ± 7.70 mg/dL.
There was a statistically significant difference in baseline characteristics based on CHI, F
(13,106) = 18.48, p < .001; Wilks’ Λ = 0.306, partial 𝜂2 = .694 (Table 5). Subjects with CHI ≤
60% were observed to have significantly lower body weight, BMI, plasma creatinine, albumin
and prealbumin levels compared to those subjects with CHI > 60%.

Prevalence of low muscularity in the cohort
Application of Model 3 to estimate UCE and subsequent calculation of CHI resulted in
mean UCE of 1102.81 ± 284.56 mg/24-hours and mean CHI of 0.65 ± 0.17. For the entire
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cohort, 33 (27.5%) were considered to have adequate muscle mass and had CHI >75%, 34
(28.3%) had CHI levels between 75-61% and considered to have mild sarcopenia and 53 (44.2%)
were found to have CHI levels ≤ 60% and were considered to have severe sarcopenia, Table 6.
Table 6. Prevalence of Sarcopenia Based on Creatinine Height Index
Degree of Sarcopenia
CHI >75%
Normal, No sarcopenia
CHI levels between 75-61%
Mild Sarcopenia
CHI levels ≤ 60%
Severe sarcopenia

Frequency
33

Percent of Total
27.5

34

28.3

53

44.2

Relationship with Malnutrition
Based on the nutrition assessment by the registered dietitian and using the AND/ASPEN
criteria for malnutrition, for the entire cohort, 50 (41.7%) were identified with malnutrition and
70 (58.3%) were identified as not having malnutrition, Table 7. Differences in prevalence of
malnutrition were noted when subjects with CHI ≤ 60% were compared to those with CHI
>60%. For subjects with CHI ≤ 60%, 36 of 53 subjects, 68%, were identified with malnutrition.
For subjects with CHI >60%, 14 of 67 subjects, 21%, were identified with malnutrition (Table 7,
Figure 1). Subjects with CHI ≤ 60%, were 8.0 times more likely to be identified with
malnutrition (OR = 8.0; 95% CI = 3.5, 18.3; p < .001), Table 8. UCE and CHI were found to be
moderately correlated to malnutrition, r = .57, p < .001 and r = .56, p < .001 respectively.
Conversely, NUTRIC score, was found to have no relationship with presence of malnutrition, r =
.004, p = .96.
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Table 7. Prevalence of Malnutrition Based on AND/ASPEN Clinical Characteristics

Number
Percent

Entire Cohort
n = 120

CHI levels > 60%

CHI levels ≤ 60%

50
41.7

14
21

36
68

n = 67

n = 53

Figure 1. Malnutrition Based on CHI Level

Percent of Patients Diagnosed with Malnutrition Based on CHI
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Table 8. Comparison of Malnutrition between Subjects with Low or Normal CHI
Outcome
a

Malnourished
= number (%)

CHI ≤ 60%a
n = 53
36 (68)

CHI > 60%a
n = 67
14 (21)
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Odds Ratio (95% CI)

p value

8.02 (3.52-18.28)

p < .001

Outcomes for the cohort
Table 9. Outcomes
________________________________________________________________
Outcome
Frequency
Percent of Total
Hosp Mortality
Yes
13
10.80
No
107
89.22
Six Month Mortality
Yes
23
19.20
No
84
70.00
NA (Died during hospital stay)
13
10.80
Malnutrition
Yes
50
41.70
No
70
58.30
Discharge Destination
Home
68
56.70
Skilled nursing facility
27
22.50
Long term acute care facility
2
1.70
Hospice
8
6.70
Transfer to another hospital
2
1.70
NA (Died during hospital stay)
13
10.80
Readmit in 30 Days
Yes
28
23.30
No
78
65.00
NA (Died during/after hospital stay) 14
11.70
Table 9 displays the overall summary of outcomes for the cohort. A total of 13 (10.8%)
of subjects expired during the hospitalization, with 107 (89.2%) surviving to be discharged. For
those who survived to discharge 68 were discharged home and 39 discharged elsewhere, with 27
discharge to a SNF, 2 discharged to a LTAC facility, 8 discharged to hospice care and two
transferred to another hospital for care not available at JAHVA. For those that were discharged
from the hospital, 28 were readmitted within 30-days and 23 expired within 6-months of initial
hospital discharge.
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The mean hospital length of stay for the entire cohort was 34.6 ± 24.6 and median 25.0
(IQR, 19.0-46.5) days. The mean ICU length of stay for the entire cohort was 14.7 ± 19.3 and
median 10.0 (IQR, 4.0-17.8) days, Table 10.
Table 10. Length of Stay

Hospital Length
of Stay
ICU Length of
Stay

Days, mean
34.6

SD
24.6

Days, median
25.0

IQR
19.0-46.5

14.7

19.3

10.0

4.0-17.8

Relationship between UCE, CHI and outcomes
Linear regression analysis determined that UCE was significantly associated with
outcomes of presence of malnutrition, hospital mortality, 6-month mortality, hospital LOS, ICU
LOS, discharge location and readmission within 30-days of discharge, r = .594, R2 = .353, (F
(7,112) = 8.72, p < .001). Similarly, using linear regression, CHI was significantly associated
with outcomes of presence of malnutrition, hospital mortality, 6-month mortality, hospital LOS,
ICU LOS, discharge location and readmission within 30-days of discharge, r = .575, R2 = .296,
(F(7,112) = 7.92, p < .001).
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Table 11. Length of Stay by Creatinine Height Index
Length of Stay
Days

Whole Cohort
(n = 120)
25.0
(19.0- 46.5)
34.6 (24.6)

Subjects with
CHI ≤ 60%
(n=53)
28.0
(20.0-55.5)
38.3 (24.5)

Subjects with
CHI >60%
(n=67)
23.0
(17.0-23.0)
31.7 (24.5)

Hospital LOS,
median (IQR)
Hospital LOS,
mean (SD)
ICU LOS, median
(IQR)
ICU LOS, mean
(SD)

10.0
(4.0-17.8)
14.7 (19.3)

11.0
(5.0-23.0)
16.7 (19.7)

8.0
(4.0-17.0)
13.6 (19.3)

p value

p = .351

p = .351

Table 11 and Figure 2 display the results of the differences in LOS by CHI. Subjects with
CHI ≤ 60% had mean hospital LOS of 38.3 ± 24.5 days compared to subjects with CHI > 60%
who had hospital LOS of 31.7 ± 24.5 days. Subjects with CHI ≤ 60% had mean ICU LOS of
16.7 ± 19.7 days compared to subjects with CHI > 60% who had ICU LOS of 13.6 ± 19.3 days.
Although differences in LOS may be clinically different, there was no statistically significant
difference in LOS based on CHI, F (2,117) = 1.06, p = .351; Wilks’ Λ = 0.982, partial 𝜂2 =
.018, Table 11.
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Figure 2. Hospital and ICU Length of Stay in Days
Hospital and ICU Length of Stay in Days
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Table 12 displays differences in outcomes by CHI. Patients with CHI ≤60% were 2.2
times more likely to die during the hospitalization, (OR = 2.2; 95% CI 0.68, 7.18; p = .19) and
2.7 times more likely to die within 6-months of discharge, (OR = 2.66; 95% CI, 1.03, 6.9; p <
.05). Patients with CHI > 60% were 1.8 times more likely to be discharged home, (OR = 1.8;
95% CI, 0.82, 4.2; p = .15). Of these outcomes, only death within 6-months of hospital discharge
met statistical significance, Figure 3. No relationship was observed between CHI and 30-day
readmission.
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Table 12. Comparison of Outcomes between Subjects with Low or Normal CHI
Outcome
Died during
hospitalization
Discharged to
location other than
home
Readmitted within
30-days
Died within 6months of
discharge
a
= number (%)

CHI ≤ 60%a
8/53 (15)

CHI > 60%a
5/67 (7)

Odds Ratio (95% CI)
2.20 (0.68-7.18)

p value
p = .19

20/45 (44)

19/62 (31)

1.81 (0.82-4.02)

p = .14

10/44 (23)

18/62 (29)

0.72 (0.29-1.76)

p = .47

14/45 (31)

9/62 (15)

2.66 (1.0-6.9)

p = .04

Figure 3. Comparison of Six-Month Mortality by CHI
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Relationship between UCE, CHI and Serum Proteins, NUTRIC and Severity of Illness
Scores
Table 13 displays the correlation between UCE, CHI and serum protein levels and
severity of illness scores. UCE and CHI were found to be only weakly associated with albumin,
r = .26, p < .005 and r = .22, p < .05, respectively. UCE and CHI were also found to be only
weakly associated with prealbumin, r = .25, p < .005 and r = .24, p < .005, respectively. UCE
and CHI were observed to have no significant relationship with serum CRP levels, r = .02, p =
.84 and r = .01, p = .94, respectively. UCE and CHI were observed to have no significant
relationship with NUTRIC score, r = .14, p = .12 and r = .03, p = .75, respectively. UCE and
CHI were also observed to have no relationship with severity of illness scores.

Table 13. Correlation between UCE, CHI, Protein Levels, Nutrition Risk and Severity of Illness
Scores
Ur Crt
CHI
Albumin Prealb
CRP NUTRIC APACHE SOFA
Ur Crt
CHI
0.93***
**
Albumin 0.26
0.22*
**
Prealb
0.25
0.24**
0.59***
***
CRP
0.02
0.01
-0.34
-0.56***
NUTRIC
-0.14
-0.03
-0.30**
-0.25**
0.15
APACHE -0.18
-0.09
-0.38***
-0.26**
0.03
0.81***
***
**
*
***
SOFA
0.06
0.11
-0.32
-0.31
0.23
0.56
0.57***
Ur Crt = urinary creatinine excretion; CHI = creatinine height index; Prealb = prealbumin
*
p < .05; **p < .01; ***p < .001
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Chapter 5: Discussion
The purpose of this research was to investigate if a valid model could be developed to
predict UCE, if the model predicted UCE was associated with known measures of muscle
measurement and if model predicted UCE had clinical utility in predicting outcomes in a cohort
of hospitalized veterans who required an ICU admission. The research included development of
models to predict UCE using input variables from 956 patients. Using the model with the best R2,
predicted UCE was compared to anthropometric measurements of muscle in a cohort of 44
subjects who had measurements obtained. Lastly, the model with the best R2 was applied
retrospectively in a cohort of 120 ICU patients and demographic and outcome variables were
examined.

Model Development
The first attempt at model development used plasma creatinine as the only input variable
to predict UCE. This was trialed as it has been previously postulated in the literature as a
potential method to predict UCE.83 In patients with a normal plasma creatinine it is reasonable to
assume that the creatinine level is a reflection of muscle mass and should be highly correlated
with measurements of muscle mass. In individuals with normal, stable renal function, variations
in muscle mass should be responsible for observed variations in plasma creatinine levels. This
study identified, that in this veteran patient population, plasma creatinine was a significant
predictor of UCE but only accounted for 5% of the variability, R2 = .0549; p <.001, with 95% of
the variance accounted for by other untested variables. This rendered the use of plasma
creatinine alone unsuitable to use for the prediction of individual UCE values. It seems
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reasonable that other variable, such as age, gender, height and weight, which can be associated
with the overall amount of muscle mass would play a role in predicting UCE.
Next, additional patient input variables, readily available on admission, were added to
develop models and improve the overall accuracy of the predictive equation. Input variables
examined for inclusion in final models were age, height, weight, gender, serum urea nitrogen,
glucose, sodium, potassium, chloride, carbon dioxide, magnesium and presence of a SCI as these
can be considered surrogates to account for total body water, extracellular water and lean body
mass.
The first model was developed for the general hospital population with plasma creatinine
≤ 1.2 mg/dL, and included patients both with and without SCI. The variables remaining in the
model included input variables of gender, age, weight, plasma creatinine and presence or absence
of SCI. A significant model was identified, R2 = .4085, p < .001, for potential use in phase 2 of
the study. The second model was developed for patients with plasma creatinine > 1.2 mg/dL.
Input variables remaining in model 2 included gender, presence or absence of SCI, age, weight,
plasma creatinine, BUN, and potassium. The identified model was also found to be significant,
R2 = .4051, p < .001. Lastly, to improve predictability further, a model was developed that
excluded patients with the presence of a SCI and included only those with normal plasma
creatinine, creatinine ≤ 1.2 mg/dL. The input variables remaining in model 3 included age,
weight, and plasma creatinine and BUN. This final non-linear model, model 3, was found to be
statistically significant, R2 = .9098, p < .001, and was selected for further investigation.
The final step in model development was validation. Model 3 was able to be validated
using two methods. First, 4-fold cross validation using the original data set was conducted
resulting in R2 of .4171, .4485, .4488 and .4488, all p < .001. Next, validation was conducted
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using a separate data set of 50 subjects that were not included in the model development. Mean
predicted UCE was 1019.46 mg ± 318.63 SD, and mean measured UCE was 1033.04 mg ±
342.08 SD. Predicted and measured UCE were found to be highly correlated, r = .716, p < .001.
Linear regression analysis yielded R2 = .502, F = 50.478, p < .001. This final model, Model 3,
was found to be highly correlated, moderately predictive and statistically significant.
The final model with the best R2, Model 3, selected for further investigation contained
more input variables than had been proposed in the literature for the development of a model.83
Creatinine is non-protein bound, diffusible across cell membranes and flows freely from one
compartment to another with the same permeability as water. The input variables remaining in
the model identified in this study are not surprising as they are surrogates for total body water,
extracellular water and lean body mass.112-114 Importantly, these input variables are all readily
available on admission. Furthermore, this model was able to estimate UCE and CHI with the
benefit of not requiring a 24-hour urine sample, which has been a limitation with using UCE or
CHI to assess muscularity.80–82 Use of a model, such as this, to estimate UCE and CHI rather
than 24-hour urine collections, in the hospital setting, can be done within minutes rather than
waiting for the urine collection and analysis. It also avoids the inconvenience and pitfalls
associated with the urine collection. This model may represent a potential surrogate “biomarker”
to screen for low muscularity shortly after admission and allow for early identification of those
patients most in need of nutrition intervention.57

Relationship between model derived CHI and muscularity
Although this model was found to be correlated and predictive of UCE, it was important
to determine if this predicted UCE was related to known measures of muscle mass. To this aim,
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this study examined if CHI, estimated from Model 3, was correlated with AC, AMA and AMC
in a subset of subjects, who had normal renal function, were without the presence of SCI, and
who had upper arm anthropometrics obtained during their nutrition assessment. Model derived
CHI was found to be strongly correlated to AC, r (42) = .665, p < .001, AMA, r (42) = .551, p <
.001, and AMC, r (42) = .559, p < .001. Overall, CHI calculated from Model 3 predicted UCE
was found to be highly correlated with accepted measures of muscularity.
Although there are a variety of techniques to measure and estimate muscle mass, such as
CT, DEXA or BIA, these advanced tools were unavailable to the dietitians at JAHVA. Some
dietitians at JAHVA, who have the skill and experience, obtain upper arm anthropometry when
doing a full nutrition assessment. Thus, for this study, anthropometric measurements were the
only available objective measures of muscularity to compare CHI against. The findings of this
study, which identified good correlation between model derived CHI and anthropometric
measures, confirms what has been found in another study that examined the relationship between
UCE and muscularity. Heymsfield et al55 demonstrated that muscle mass, as estimated from
upper arm anthropometry, was strongly correlated with UCE, r = .94, p < .001. Lambell et al115
recently demonstrated that the bedside technique of upper arm anthropometry was strongly
correlated with CT measured muscle area, r = .67, p < .001. UCE has also been found to be
strongly correlated with LBM as measure by K40 counting and by densitometry and deuterium
dilution.59-61 Thus, the model identified in this study was found to be highly correlated and
moderately predictive of UCE and was also strongly correlated with a known objective measure
of muscularity.

64

Model Application
The second phase of this study sought to examine if UCE and CHI, derived from Model 3
had potential clinical usefulness. Phase 2 of the research was conducted by retrospectively
applying the model to a cohort of 120 veterans who had been hospitalized and required an ICU
admission. Phase 2 examined if UCE was associated with or predicted outcomes of malnutrition,
mortality, discharge location or readmission.

Baseline Demographics
Baseline demographics of the cohort are reported on Table 5. As this study was
conducted at a Veterans Affairs hospital, all subjects were male, and the median age was 69.08 ±
8.7 years. The cohort had a mean height of 176.4 ± 6.8 cm, mean weight of 83.5 ± 19.5 kg, and
mean BMI of 26.9 ± 6.4, which could imply that the group was well nourished. However, as
weight or BMI may be poorly correlated with muscle mass, reliance on these measures may
result in the clinician failing to identify low muscle mass and ultimately prevent the clinician
from directing their interventions accordingly and should be viewed with caution.19,29-32
The mean severity of illness scores for the cohort were APACHE II 15.93 ± 4.88, which
is associated with a 12-24% risk of mortality, and SOFA score 3.59 ± 2.64, which is associated
with a <10% risk of mortality.116-117 As such, the cohort for this study is considered to have a
lower risk for mortality.
The mean serum protein levels, on the day of the nutrition assessment, were albumin 2.55
± 0.58 g/dL, prealbumin 10.48 ± 5.66 mg/dL and CRP 9.46 ± 7.70 mg/dL. This reduction from
normal levels in albumin and prealbumin occurs in the presence of an inflammatory response,
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which is reflected by the elevated CRP level and is commonly observed in the critically ill,
regardless of nutrition status.118-119
When the cohort was examined by whether or not subjects had CHI ≤ 60%, considered
to be sarcopenic, compared to >60%, some differences between the groups were noted.
MANOVA analysis identified a statistically significant difference in baseline characteristics
based on CHI, F (13,106) = 18.48, p < .001; Wilks’ Λ = 0.306, partial 𝜂2 = .694 (Table 5).
Subjects with CHI ≤ 60% were observed to have significantly lower body weight, BMI, plasma
creatinine, albumin and prealbumin levels compared to those subjects with CHI > 60%. A higher
body weight and higher BMI may not always indicate greater lean body mass, as in those with
sarcopenic obesity.19,29-32 However in this study, those with sarcopenia as identified with model
derived CHI, did have significantly lower weight and BMI.
As plasma creatinine varies directly and proportionally with muscle mass, in those with
normal renal function, and plasma creatinine levels have been strongly correlated with lean body
mass, it was expected that those with low CHI would have lower plasma creatinine.54-57 This was
confirmed by the findings observed in this cohort as those subjects with low CHI had
significantly lower plasma creatinine levels (Table 5).
The differences in albumin and prealbumin levels, between those with CHI >60%
compared to those with CHI ≤ 60%, observed in this study was unexpected as the CRP levels
were not different between the groups. In acute illness, some protein levels change in response to
cytokines. Those proteins that increase in concentration are referred to as positive acute phase
proteins and include CRP and ceruloplasmin. Other proteins fall in the face of an inflammatory
response and these are referred to as negative acute phase proteins and include albumin,
prealbumin and transferrin.118 As serum albumin and prealbumin are presently considered to be
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associated with inflammation and not markers of nutrition status, one would have expected that
lower levels would be observed in the presence of higher CRP levels and thus be similarly low in
both groups.118-120 However, this was not observed. It should be noted that both groups
demonstrated below normal albumin and prealbumin levels and elevated CRP levels as expected
in the critically ill. Additionally, the severity of illness scores, APACHE II and SOFA, were not
different between the two groups. Previous studies have demonstrated that albumin and
prealbumin were correlated with measures of inflammation and did not change in response to
nutrition intervention.118,121-122
It has recently been suggested that low circulating levels of albumin suggests a long-term
insufficient nitrogen intake and that treatment should be focused on resolving inflammation and
provision of nitrogen.123 Other potential explanations for the lower levels of albumin and
prealbumin observed in those with sarcopenia in this study may be extrapolated from what is
known about skeletal muscle. Skeletal muscle is an important metabolically active organ, and
plays key roles in protein synthesis.19,20 In the adequately fed state, amino acids from food
supply the needed precursors for new protein synthesis. When nutrient intake is insufficient,
muscle protein becomes the principal reservoir of the needed amino acids.21 Normal protein
turnover and synthesis can continue provided adequate muscle mass is available for
cannibalism.21 In the setting of acute illness, requirements for amino acids from skeletal muscle
increases due to increased synthesis of acute phase proteins, synthesis of protein components of
the immune system and synthesis of proteins necessary for wound healing.12,20–22 It could be
hypothesized that the lower albumin and prealbumin levels seen in the group with sarcopenia
reflects the lack of available amino acid substrates from skeletal muscle necessary for protein
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synthesis. As this study was not designed to address this interesting finding, it will require
additional investigation.

Prevalence of low muscularity in the cohort
Application of Model 3 to estimate UCE and subsequent calculation of CHI resulted in
mean UCE of 1102.81 ± 284.56 mg/24-hours and mean CHI of 0.65 ± 0.17. For the entire
cohort, 33 (27.5%) were considered to have adequate muscle mass and had CHI >75%, 34
(28.3%) had CHI levels between 75-61% were considered to have mild sarcopenia and 53
(44.2%) were found to have CHI levels ≤ 60% and were considered to have severe sarcopenia.
Others have reported varying rates of prevalence of sarcopenia in the critically ill, mostly
through the use of CT scans. Joyce et al36 reported a prevalence of sarcopenia of 68% in their
cohort of ICU patients. Looijard et al17 observed a 60% prevalence of low skeletal muscle area
using CT scans in their cohort of ICU patients and Weijs et al28 reported a 63% prevalence.
Using DEXA, Abramowitz et al41 reported that 14% of their study cohort had sarcopenia.
Differences in the reported prevalence of sarcopenia in these ICU patients and our findings may
reflect the different method of measurement, CT versus DEXA, and for this study, an indirect
method of estimating muscularity. However, the findings of this study, a prevalence of 44%,
appear reasonable and within the range of what others have reported.

Relationship with Malnutrition
Based on the nutrition assessment by the registered dietitian and using the AND/ASPEN
criteria for malnutrition, for the entire cohort, 50 (41.7%) were identified with malnutrition and
70 (58.3%) were identified as not having malnutrition, Table 7. Varying prevalence of
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malnutrition in the critically ill have been reported. A recent review of 20 studies found the
prevalence of malnutrition to be from 38% to 78%.124 These widely varying rates are generally
considered to be due to different tools and different criteria utilized to diagnosis malnutrition and
include the use of Subjective Global Assessment, the Mini Nutritional Assessment or the
Malnutrition Universal Screening Tool.124 The AND/ASPEN publication of standardized
malnutrition diagnostic criteria has allowed more uniform analysis and comparisons between
groups.31 A recent study by Hiura et al125 utilized the standardized malnutrition diagnostic
criteria and identified a 23.9% and 21.1% prevalence of severe malnutrition in the medical ICU
and surgical ICU respectively. Unfortunately, Hiura et al125 did not report the prevalence of
moderate malnutrition in their groups so the overall prevalence of malnutrition is unclear. The
findings of this current study of a 41.7% prevalence of malnutrition in the cohort is in line with
the findings of others.124-125
Differences in prevalence of malnutrition were noted when subjects with CHI ≤ 60%
were compared to those with CHI >60%. For subjects with CHI ≤ 60%, 36 of 53 subjects, 68%,
were identified with malnutrition, Figure 1. For subjects with CHI >60%, 14 of 67 subjects,
21%, were identified with malnutrition. Subjects with CHI ≤ 60%, were 8.0 times more likely to
be identified with malnutrition (OR = 8.0; 95% CI = 3.5, 18.3; p < .001), Table 8. These findings
are consistent with the AND/ASPEN standardized malnutrition diagnostic criteria as two of the
diagnostic criteria, loss of muscle mass and diminished functional status as measured by hand
grip strength, involve measurements of muscle mass and identification of sarcopenia.31
Importantly, applying Model 3 retrospectively to a cohort of patients identified, on admission,
those that would be diagnosed with malnutrition.
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Conversely, the NUTRIC score, was found to have no relationship with presence of
malnutrition, r = .004, p = .96. The NUTRIC score, although commonly used as a nutrition
screening tool for ICU patients, was designed to identify ICU patients who would benefit from
prompt nutrition intervention and not screen for malnutrition or nutrition risk.105 The NUTRIC
score does not actually include any classic nutrition indicators, but is scored based on age,
APACHE 2 score, SOFA score, number of co-morbidities, numbers of days from hospital
admission to ICU admission and Interleukin 6 level, a pro-inflammatory cytokine.105 In this
study, reliance on the NUTRIC score, alone, to screen patients would have failed to identify
those with malnutrition and possibly delayed nutrition intervention.

Outcomes for the cohort
A total of 13 (10.8%) subjects expired during the hospitalization. This confirms predicted
estimates from the mean APACHE 2 and SOFA scores with anticipated mortality rates of 1224% and <10% respectively. Overall, the mean hospital LOS was 34.6 ± 24.6 days and the mean
ICU LOS for was 14.7 ± 19.3 days (Table 10). Of the 107 patients who were discharged, 28
were readmitted within 30-days and 23 expired within 6-months of discharge.

Relationship between UCE, CHI and Outcomes
This study identified, with linear regression analysis, that UCE and CHI, were both
significantly associated with the outcomes of presence of malnutrition, hospital mortality, 6month mortality, hospital LOS, ICU LOS, discharge location and readmission within 30-days of
discharge, r = .594, R2 = .353, p < .001 and r = .575, R2 = .296, p < .001, respectively.
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Several important differences in outcomes were also observed when subjects with CHI ≤
60% were compared with those CHI > 60% (Table 11, Table 12, Figure 2, Figure 3). Patients
with low CHI were 2.2 times more likely to die during the hospitalization, 1.8 times more likely
to be discharged to a location other than their home, and 2.66 times more likely to expire within
6 months of discharge. However, difference in six-month mortality was the only outcome that
met statistical significance. Hospital and ICU LOS was longer for those patients with CHI ≤
60% and could represent a clinical difference however did not meet statistical significance.
The findings of this study of worse outcomes, or a trend towards worse outcomes, in
those with low muscularity, coincides with the findings of others which have used various
methods to estimate muscle mass. Previous research using CT scans to identify low muscularity
have identified an increase in hospital, 30-day, 60-day, 6-month or 1-year mortality in those with
sarcopenia.17,28,37,38,40 Sarcopenia identified with BIA has also been found to be associated with
28-day mortality.33 Other studies have identified significant relationships between sarcopenia
and increased hospital LOS using CT or US measurements.35,36 Lastly, Hessels et al66 identified
a significant relationship between UCE and hospital mortality. This study, by use of a model,
was able to obtain similar findings without the use of invasive testing or a 24-hour urine
collection.

Strengths of the Study
Strengths of this study include the availability of a large de-identified data set from which
models could be constructed and validated. Additionally, as this data set came from a specific
patient population, identified models were highly predictive. Also, the model identified was
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simple enough that it can be easily applied by the average clinician and utilized variables that are
available for patients shortly after admission.
Several strengths for the design of Phase 2 have been identified. The data collected was
readily available within the EMR. Limiting application of the model in Phase 2 to only ICU
patients minimized heterogeneity of the study population. Limiting the study population to those
that had received a full nutrition assessment by the RDN allowed comparison of model derived
UCE and CHI to the presence or absence of malnutrition. Extensive documentation and
laboratory testing are done for all patients who receive full nutrition assessments minimizing the
likelihood of missing data. Lastly, collecting data during the selected time period ensured that the
AND/ASPEN malnutrition criteria were used to identify malnutrition and avoided confounders
of differing definitions or criteria of malnutrition.

Limitations of the Study
For Phase 1 several weaknesses are acknowledged. Models are strongly linked to the
population which they were derived from, thus the model identified in this study, developed from
a group of veterans, may be less applicable in other populations. As this study was conducted at
a Veterans’ hospital, although data from females was not excluded, female data would be
underrepresented in the deidentified data set from which the models were built. For the
development of the models, the study assumes that there have been accurate 24-hour urine
collections. Cases in which the collection lasts for more or less than 24-hours or in which some
urine is lost may result in inaccurate estimates of 24-hour creatinine excretion. Lastly, there is a
risk that some patients had elevated UCE not due to increased muscle mass but rather due to
consumption of a very high protein diet or certain amino acid supplements.
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For Phase 2 of the study additional limitations are acknowledged. Limitations associated
with retrospective studies and small sample size may have precluded definitive results.
Retrospective studies have the limitation of only identifying associations and not causation.
These results may not be generalizable to females, non-veterans and patients of different age
groups. The results will also not be applicable to patients with admission plasma creatinine levels
of >1.2 mg/dL. It is unclear if these results would hold up if applied to those patients who had
not received a full nutrition assessment or who were not ICU patients. Unfortunately, the sample
size was too small to detect differences in LOS. These results may also not be applicable to
patients with different medical acuity levels, represented by APACHE 2 and SOFA scores, as
JAHVA has a patient acuity similar to a community hospital.

Chapter 6: Conclusions, Implications for Practice and Recommendations for Future
Research

Conclusions
The primary aim of this research was to determine if 24-hour UCE can be reliably
estimated from plasma creatinine or other patient variables by the development of a model and if
the model can be validated. Additional aims of the study were to determine if low muscularity
based on model derived CHI is correlated to low muscularity based on anthropometric
measurements. The last aim was to apply the model to a cohort of hospitalized critically ill
veterans, to describe the degree of low muscle mass observed and determine if model derived
UCE and CHI are associated with other assessment measures and outcomes.

73

The study successfully identified a final model to estimate UCE utilizing the input
variables of plasma creatinine, plasma BUN, age and weight. Each remaining input variable was
found to be independently statistically significant. The final model was found to be highly
correlated, moderately predictive of UCE and statistically significant. This model was then
appropriately validated using two methods, four-fold cross validation and using a separate data
set of subjects not used to construct the model. Next, the study sought to determine if model
derived CHI was correlated to known measures of muscularity. Using a subset of patients in
whom anthropometric measurements were obtained, the study identified that model derived CHI
was highly correlated with arm muscle area, arm muscle circumference and arm circumference.
In Phase 2 of the study, the model was retrospectively applied to a group of critically ill
veterans. The model identified that 44.2% of the subjects were found to have CHI levels ≤ 60%
and were considered to have severe sarcopenia. Subjects with model estimated CHI ≤ 60% were
found to have significantly lower body weight, BMI, plasma creatinine, albumin and prealbumin
levels. Subjects with CHI ≤ 60% were found to be 8.0 times more likely to be diagnosed with
malnutrition and 2.6 times more likely to be readmitted in 6 months. Subjects with low CHI
trended towards longer hospital and ICU LOS, however it did not meet statistical significance.
Lastly, a commonly used ICU nutrition screening tool, NUTRIC, was found to have no
relationship with the presence of malnutrition.

Implications for practice
The development of a model which predicts UCE and correlates with muscle mass offers
a novel method for the RDN to readily identify patients with sarcopenia on hospital admission.
This method could allow the RDN to quickly screen new admissions for potential sarcopenia
without the use of CT or DEXA scans and without the inconvenience of a 24-hour urine
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collection by using readily available patient variables. A model such as this is also ideally suited
to be automatically computer generated.
Recent recommendations have been made that muscle mass should be at the core of
nutrition screening and management strategies, and that tools and techniques be developed to
assess muscle mass.19 As nutrition screening is moving away from evaluation of weight and
towards identifying sarcopenia, this study potentially fills a gap by providing a clinical tool to
accomplish this. This would thus allow the RDN to begin prompt nutrition intervention to those
patients most in need.

Recommendations for future research
This study was limited by applying the identified model in a retrospective fashion to a
group of critically ill veterans. Several future research studies are warranted to determine the
applicability of the model to other populations. First, research should be designed to apply the
model in a prospective fashion to the same patient population, using a larger sample size, to
determine if the findings are consistent and if additional relationships with outcomes can be
identified. Next, the model could be applied prospectively to sample populations of hospitalized
veterans admitted to the general medical and surgical wards. This would allow analysis of the
model’s ability to function as an admission nutrition screening tool. If these studies demonstrate
positive findings, the model could then be applied to non-veteran patient populations.
Lastly, the findings of differences in albumin and pre-albumin levels between those
subjects with or without sarcopenia was unexpected. These findings should be explored with an
appropriately powered study examining relationships between these serum protein levels and
direct and indirect measures of muscularity.
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